{"content":"<li class=\"n-box-item date-title\" data-end=\"1498795199\" data-start=\"1498708800\" data-txt=\"Monday, December 23, 2019\">Thursday, June 29, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3276429\" data-ts=\"1498773629\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DLR\" target=\"_blank\">DLR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276429-digital-realty-wraps-135m-refinancing-on-exchange-in-jv\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Digital Realty wraps $135M refinancing on exchange in JV</a></h4><ul>   <li>Digital Realty (<a href=\"http://seekingalpha.com/symbol/DLR\" target=\"_blank\">DLR</a> <font color='red'>-2.1%</font>) has wrapped a <a href=\"https://seekingalpha.com/pr/16876648-digital-realty-joint-venture-completes-135-million-secured-debt-refinancing\" target=\"_blank\">$135M mortgage refinancing</a> on a property it holds in a joint venture.</li>    <li>The company closed a 10-year 3.29% mortgage on the Westin Building Exchange in Seattle, a key Internet exchange for the Pacific Northwest. That loan replaces a $101M secured loan bearing interest at 6.37% that matures in September.</li>    <li>It holds that property in a 50/50 JV with Clise Properties.</li>    <li>The new loan is interest-only with the principal due at maturity.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3276429\" data-linked=\"Digital Realty wraps $135M refinancing on exchange in JV\" data-tweet=\"$DLR - Digital Realty wraps $135M refinancing on exchange in JV https://seekingalpha.com/news/3276429-digital-realty-wraps-135m-refinancing-on-exchange-in-jv?source=tweet\" data-url=\"https://seekingalpha.com/news/3276429-digital-realty-wraps-135m-refinancing-on-exchange-in-jv\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276424\" data-ts=\"1498772141\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276424-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/HAIN' title='The Hain Celestial Group, Inc.'>HAIN</a> <font color='green'>+7.2%</font>. <a href='https://seekingalpha.com/symbol/DERM' title='Dermira'>DERM</a> <font color='green'>+4.5%</font>. <a href='https://seekingalpha.com/symbol/NKE' title='Nike Inc.'>NKE</a> <font color='green'>+3.6%</font>. <a href='https://seekingalpha.com/symbol/KGC' title='Kinross Gold Corporation'>KGC</a> <font color='green'>+3.0%</font>. <a href='https://seekingalpha.com/symbol/XIV' title='VelocityShares Daily Inverse VIX Short-Term ETN'>XIV</a> <font color='green'>+2.2%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/CARA' title='Cara Therapeutics Inc.'>CARA</a> <font color='red'>-31.4%</font>. <a href='https://seekingalpha.com/symbol/AOBC' title='American Outdoor Brands Corporation'>AOBC</a> <font color='red'>-10.2%</font>. <a href='https://seekingalpha.com/symbol/TVIX' title='VelocityShares Daily 2x VIX Short-Term ETN'>TVIX</a> <font color='red'>-3.5%</font>. <a href='https://seekingalpha.com/symbol/HESM' title='Hess Midstream Partners LP'>HESM</a> <font color='red'>-3.4%</font>. <a href='https://seekingalpha.com/symbol/ALKS' title='Alkermes plc'>ALKS</a> <font color='red'>-2.8%.</font></li> </ul><div class=\"tiny-share-widget\" data-id=\"3276424\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$HAIN $DERM $NKE - After Hours Gainers / Losers https://seekingalpha.com/news/3276424-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3276424-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276413\" data-ts=\"1498769446\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALKS\" target=\"_blank\">ALKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276413-alkermes-antipsychotic-candidate-alks-3831-successful-in-late-stage-schizophrenia-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alkermes antipsychotic candidate ALKS 3831 successful in late-stage schizophrenia study, but weight gain may be issue; shares down 3% after hours</a></h4><ul><li>Alkermes (NASDAQ:<a href='https://seekingalpha.com/symbol/ALKS' title='Alkermes plc'>ALKS</a>) <a href=\"https://seekingalpha.com/pr/16876455-alkermes-announces-positive-preliminary-topline-results-phase-3-antipsychotic-efficacy-study\" target=\"_blank\">announces </a>positive results from a Phase 3 clinical trial, ENLIGHTEN-1, assessing ALKS 3831 for the treatment of schizophrenia. The three-arm study compared the antipsychotic against placebo and olanzapine (Eli Lilly's Zyprexa).</li><li>The study showed treatment with ALKS 3831 produced a statistically significantly greater reduction in symptoms compared to placebo (p&lt;0.001), the primary endpoint. Treatment with olanzapine also showed the same benefit versus control (p=0.004).</li><li>The company was not specific on the degree and incidence of adverse events, but stated that the most common AEs in both the ALKS 3831 and olanzapine groups were weight gain, drowsiness and dry mouth.</li><li>Investors appear cautious with the AE data since the main value proposition of ALKS 3831 is comparable efficacy versus olanzapine with less effect on weight gain.</li><li>Complete data will be submitted for presentation at an upcoming medical conference and for publication.</li><li>Shares are off&nbsp;<font color='red'>3%</font>&nbsp;after hours on average volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3276413\" data-linked=\"Alkermes antipsychotic candidate ALKS 3831 successful in late-stage schizophrenia study, but weight gain may be issue; shares down 3% after hours\" data-tweet=\"$ALKS - Alkermes antipsychotic candidate ALKS 3831 successful in late-stage schizophrenia study, but weight gain may be issue; shares down 3% after hours https://seekingalpha.com/news/3276413-alkermes-antipsychotic-candidate-alks-3831-successful-in-late-stage-schizophrenia-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3276413-alkermes-antipsychotic-candidate-alks-3831-successful-in-late-stage-schizophrenia-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276411\" data-ts=\"1498769305\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZAYO\" target=\"_blank\">ZAYO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276411-zayo-group-prices-300m-in-debt\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zayo Group prices $300M in debt</a></h4><ul>   <li>Zayo Group (<a href=\"http://seekingalpha.com/symbol/ZAYO\" target=\"_blank\">ZAYO</a> <font color='red'>-1.8%</font>) has <a href=\"https://seekingalpha.com/pr/16876494-zayo-group-llc-prices-300-million-senior-notes-offering\" target=\"_blank\">priced an offering</a> of $300M in debt.</li>    <li>The company is engaging in a private offering of that amount in 5.75% senior notes due 2027 via an add-on.</li>    <li>It expects to use proceeds to partly repay an outstanding term loan.</li>    <li>At last report the company had total debt of $5.61B, with total cash of $198.4M.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3276411\" data-linked=\"Zayo Group prices $300M in debt\" data-tweet=\"$ZAYO - Zayo Group prices $300M in debt https://seekingalpha.com/news/3276411-zayo-group-prices-300m-in-debt?source=tweet\" data-url=\"https://seekingalpha.com/news/3276411-zayo-group-prices-300m-in-debt\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:48 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276404\" data-ts=\"1498768401\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HAIN\" target=\"_blank\">HAIN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276404-engaged-capital-discloses-10-stake-in-hain-celestial\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Engaged Capital discloses 10% stake in Hain Celestial</a></h4><ul><li>Engaged Capital reports it holds a 9.9% stake in Hain Celestial (NASDAQ:<a href='https://seekingalpha.com/symbol/HAIN' title='The Hain Celestial Group, Inc.'>HAIN</a>).</li><li><a href=\"https://seekingalpha.com/filing/3610102\" target=\"_blank\">SEC Form 13D</a></li><li>HAIN&nbsp;<font color='green'>+1.68%</font>&nbsp;AH to $36.36.</li></ul><div class=\"tiny-share-widget\" data-id=\"3276404\" data-linked=\"Engaged Capital discloses 10% stake in Hain Celestial\" data-tweet=\"$HAIN - Engaged Capital discloses 10% stake in Hain Celestial https://seekingalpha.com/news/3276404-engaged-capital-discloses-10-stake-in-hain-celestial?source=tweet\" data-url=\"https://seekingalpha.com/news/3276404-engaged-capital-discloses-10-stake-in-hain-celestial\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276402\" data-ts=\"1498768181\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKE\" target=\"_blank\">NKE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276402-global-markets-help-nike-fly-past-estimates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Global markets help Nike fly past estimates</a></h4><ul>     <li>Nike (NYSE:<a href='https://seekingalpha.com/symbol/NKE' title='Nike Inc.'>NKE</a>) reports sales rose 7% in <a href=\"https://seekingalpha.com/pr/16876509-nike-inc-reports-fiscal-2017-fourth-quarter-full-year-results\" target=\"_blank\">FQ4</a>&nbsp; to $8.7B on a constant currency basis.</li>     <li>Revenue by brand (ex-currency): Nike +7% to $8.1B, Converse +10% to $554M.</li>          <li>Nike running brand revenue rose 8% to $5.28B during the quarter, while Nike basketball brand fell 5% and the Jordan brand rose 13%. Sportswear revenue was up 17% to $8.59B.</li><li>Nike brand apparel sales increased 10% (constant currency)&nbsp;during the quarter, while footwear sales rose 4%.</li>          <li>Gross margin -180 bps Y/Y to 44.1% as higher product costs offset an improvement in selling prices. Analysts expected a mark of 44.3%.</li>     <li>The company's effective tax rate was 13.7% for the period vs. 21.2% last year. A high mix of non-U.S. revenue impacted the comparison.</li>  <li>For the full fiscal year, Nike digital commerce sales popped 30% Y/Y to help lift the DTC channel to a 18% gain in revenue to $9.1B.</li>     <li>\"We&rsquo;re putting even more firepower behind our greatest opportunities in Fiscal 2018. It will be a big year for NIKE innovation and we&rsquo;ll bring those stories to life through deeper consumer connections in our key cities around the world,\" extolls Nike CEO Mark Parker.</li>     <li>Nike is due to give out future orders guidance on the conference call. The consenus estimate is +1.25% (constant currency). Futures orders in North America are expected to fall 6.1%.</li>     <li>Previously: <a href=\"https://seekingalpha.com/news/3276393-nike-beats-0_10-beats-revenue\" target=\"_blank\">Nike beats by $0.10, beats on revenue</a> (June 29)</li>     <li>NKE&nbsp;<font color='green'>+3.12%</font>&nbsp;AH<font color='red'>&nbsp;</font>to $54.83.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3276402\" data-linked=\"Global markets help Nike fly past estimates\" data-tweet=\"$NKE - Global markets help Nike fly past estimates https://seekingalpha.com/news/3276402-global-markets-help-nike-fly-past-estimates?source=tweet\" data-url=\"https://seekingalpha.com/news/3276402-global-markets-help-nike-fly-past-estimates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276401\" data-ts=\"1498768091\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276401-micron-q3-beats-estimates-ocf-doubled-on-year-shares-up-aftermarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Micron Q3 beats estimates, OCF doubled on year; shares up aftermarket</a></h4><ul><li>        Micron Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a>) <a href=\"https://seekingalpha.com/pr/16876458-micron-technology-inc-reports-results-third-quarter-fiscal-2017\" target=\"_blank\">reports</a> Q3 results with EPS and revenue beats. Revenue growth primarily due to 14% increase in DRAM selling prices and 17% increase in trade NAND sales volumes.</li><li>               Non-GAAP gross margin was 48% due to lower manufacturing costs for NAND and DRAM and the lower selling prices.&nbsp;</li><li>               CapEx was $1.27B and Micron ended the quarter with $4.93 in cash and short-term investments. Cash flow from operations more than doubled on the year to $4.9B.&nbsp;</li><li><a href=\"https://seekingalpha.com/pr/16876458-micron-technology-inc-reports-results-third-quarter-fiscal-2017\" target=\"_blank\">               Press release&nbsp;</a></li><li>               Micron Technology shares are&nbsp;<font color='green'>up 0.89%</font>&nbsp;aftermarket after a <a href=\"https://seekingalpha.com/news/3276355-s-and-p-nasdaq-new-tech-pullback-semiconductors-take-hit\" target=\"_blank\">rough day</a> for semiconductor stocks.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3276385-micron-technology-beats-0_11-beats-revenue\" target=\"_blank\">Micron Technology beats by $0.11, beats on revenue</a> (June 29)</li></ul><div class=\"tiny-share-widget\" data-id=\"3276401\" data-linked=\"Micron Q3 beats estimates, OCF doubled on year; shares up aftermarket\" data-tweet=\"$MU - Micron Q3 beats estimates, OCF doubled on year; shares up aftermarket https://seekingalpha.com/news/3276401-micron-q3-beats-estimates-ocf-doubled-on-year-shares-up-aftermarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3276401-micron-q3-beats-estimates-ocf-doubled-on-year-shares-up-aftermarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>96&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276399\" data-ts=\"1498768066\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CARA\" target=\"_blank\">CARA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276399-cara-therapeutics-oral-tablet-version-of-pain-candidate-cr845-shows-mixed-results-in-mid\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cara Therapeutics oral tablet version  of pain candidate CR845 shows mixed results in mid-stage study; shares down 22% after hours</a></h4><ul><li>A Phase 2b clinical trial assessing an oral tablet formulation of Cara Therapeutics' (NASDAQ:<a href='https://seekingalpha.com/symbol/CARA' title='Cara Therapeutics Inc.'>CARA</a>) CR845 in patients with osteoarthritis &#40;OA&#41;&nbsp;of the knee or hip <a href=\"https://seekingalpha.com/pr/16876464-cara-therapeutics-announces-top-line-results-phase-2b-trial-oral-cr845-chronic-pain-patients\" target=\"_blank\">demonstrated </a>a statistically significant reduction in mean joint pain score versus placebo (p=0.043) in patients with OA of the hip who received the highest dose of 5.0 mg. In all OA patients treated with 5.0 mg, however, the reduction in mean joint pain score reduction of 35% fell short of statistical significance (p=0.111).</li><li>Patients treated with the 1.0 mg and 2.5 mg strengths did not experience significant reductions in mean joint pain scores versus placebo.</li><li>The company is also developing an IV formulation of CR845 for the treatment of uremic pruritis in kidney disease patients and postoperative pain.</li><li>Management will host a conference call momentarily to discuss the results.</li><li>Shares are down&nbsp;<font color='red'>22%</font>&nbsp;after hours on robust volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3276399\" data-linked=\"Cara Therapeutics oral tablet version  of pain candidate CR845 shows mixed results in mid-stage study; shares down 22% after hours\" data-tweet=\"$CARA - Cara Therapeutics oral tablet version of pain candidate CR845 shows mixed results in mid-stage study; shares down 22% after hours https://seekingalpha.com/news/3276399-cara-therapeutics-oral-tablet-version-of-pain-candidate-cr845-shows-mixed-results-in-mid?source=tweet\" data-url=\"https://seekingalpha.com/news/3276399-cara-therapeutics-oral-tablet-version-of-pain-candidate-cr845-shows-mixed-results-in-mid\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>60&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276397\" data-ts=\"1498767753\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EXFO\" target=\"_blank\">EXFO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276397-exfo-sees-revenues-fall-and-miss-offers-light-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Exfo sees revenues fall and miss, offers light guidance</a></h4><ul>   <li>Exfo (<a href=\"http://seekingalpha.com/symbol/EXFO\" target=\"_blank\">EXFO</a> <font color='red'>-3.9%</font>) saw revenues decline and miss and provided downside guidance with its <a href=\"https://seekingalpha.com/news/3276388-exfo-eps-0_08\" target=\"_blank\">fiscal Q3 earnings</a>.</li>    <li>A restructuring plan it announced in early May added $3.8M in charges but is expected to generate annual savings of $8M: \"We should begin beneftting from our restructuring efforts in the fourth quarter, but the full impact will be felt in fiscal 2018,\" says CEO Philippe Morin.</li>    <li>EBITDA of $2.3M missed an expected $4.3M. Bookings hit $63.7M, and book-to-bill ratio is at 1.09.</li>    <li>Sales breakout: Physical-layer, $41M (down 2.5%); Protocol-layer, $17.7M (down 8.2%)</li>    <li>For Q4, it's guiding to sales of $58M-$63M (light of consensus for $66.6M) and EPS from -$0.03 to $0.01 (below consensus for $0.08).</li>    <li><a href=\"http://edge.media-server.com/m/p/453ny4wf\" target=\"_blank\">Conference call</a> to come at 5 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/16876488-exfo-reports-third-quarter-results-fiscal-2017\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3276397\" data-linked=\"Exfo sees revenues fall and miss, offers light guidance\" data-tweet=\"$EXFO - Exfo sees revenues fall and miss, offers light guidance https://seekingalpha.com/news/3276397-exfo-sees-revenues-fall-and-miss-offers-light-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3276397-exfo-sees-revenues-fall-and-miss-offers-light-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:22 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276393\" data-ts=\"1498767356\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKE\" target=\"_blank\">NKE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276393-nike-beats-0_10-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nike beats by $0.10, beats on revenue</a></h4><ul><li>Nike (NYSE:<a href='https://seekingalpha.com/symbol/NKE' title='Nike Inc.'>NKE</a>): Q4 EPS of $0.60 <font color='green'>beats by $0.10</font>.</li><li>Revenue of $8.68B (+5.3% Y/Y) <font color='green'>beats by $40M</font>.</li><li>Shares <font color='green'>+1.15%</font>.</li><li><a href='https://seekingalpha.com/pr/16876509-nike-inc-reports-fiscal-2017-fourth-quarter-full-year-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3276393\" data-linked=\"Nike beats by $0.10, beats on revenue\" data-tweet=\"$NKE - Nike beats by $0.10, beats on revenue https://seekingalpha.com/news/3276393-nike-beats-0_10-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3276393-nike-beats-0_10-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276385\" data-ts=\"1498766539\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276385-micron-technology-beats-0_11-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Micron Technology beats by $0.11, beats on revenue</a></h4><ul><li>Micron Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a>): Q3 EPS of $1.62 <font color='green'>beats by $0.11</font>.</li><li>Revenue of $5.57B (+92.1% Y/Y) <font color='green'>beats by $160M</font>.</li><li>Shares <font color='green'>+1.05%</font>.</li><li><a href='https://seekingalpha.com/pr/16876458-micron-technology-inc-reports-results-third-quarter-fiscal-2017'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3276385\" data-linked=\"Micron Technology beats by $0.11, beats on revenue\" data-tweet=\"$MU - Micron Technology beats by $0.11, beats on revenue https://seekingalpha.com/news/3276385-micron-technology-beats-0_11-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3276385-micron-technology-beats-0_11-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>168&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276374\" data-ts=\"1498764069\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHFS\" target=\"_blank\">CHFS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276374-stanford-on-go-clinical-study-to-evaluate-chfs-aquadex-in-children-heart-failure-shares-up-50\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stanford on go with clinical study to evaluate CHF&#39;s Aquadex in children with heart failure; shares up 50%</a></h4><ul><li>Thinly traded nano cap CHF Solutions (<a href='https://seekingalpha.com/symbol/CHFS' title='CHF Solutions, Inc.'>CHFS</a> <font color='green'>+49.5%</font>) is up on a healthy 17x surge in volume in response to its <a href=\"https://seekingalpha.com/pr/16875526-chf-solutions-aquadex-flexflow-aquapheresis-system-receives-fda-ide-approval-clinical-study\" target=\"_blank\">announcement </a>that Stanford University School of Medicine's Department of Pediatrics has received an Investigational Device Exemption &#40;IDE&#41; from the FDA to conduct a 45-subject study assessing its Aquadex FlexFlow Aquapheresis System for the treatment of diuretic-resistant fluid overload in children with acute decompensated heart failure.</li><li>The objective of the study is to determine whether Aquadex can produce greater weight loss and a non-inferior rate of renal dysfunction compared to optimal therapy. Secondary endpoints include its effect on heart failure symptoms.</li><li>The company was formerly known as Sunshine Heart, which adopted the new name a month ago.</li></ul><div class=\"tiny-share-widget\" data-id=\"3276374\" data-linked=\"Stanford on go with clinical study to evaluate CHF&#39;s Aquadex in children with heart failure; shares up 50%\" data-tweet=\"$CHFS - Stanford on go with clinical study to evaluate CHF&#39;s Aquadex in children with heart failure; shares up 50% https://seekingalpha.com/news/3276374-stanford-on-go-clinical-study-to-evaluate-chfs-aquadex-in-children-heart-failure-shares-up-50?source=tweet\" data-url=\"https://seekingalpha.com/news/3276374-stanford-on-go-clinical-study-to-evaluate-chfs-aquadex-in-children-heart-failure-shares-up-50\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276373\" data-ts=\"1498763471\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CEL\" target=\"_blank\">CEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276373-cellcom-adds-ginx-esports-to-tv-service\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cellcom adds Ginx Esports to TV service</a></h4><ul>   <li>Cellcom Israel (NYSE:<a href='https://seekingalpha.com/symbol/CEL' title='Cellcom Israel, Ltd.'>CEL</a>) is <font color='green'>up 3%</font> today and hitting its highest point on the NYSE in three weeks.</li>    <li>In Tel Aviv, the stock closed <font color='green'>up 2.3%</font>.</li>    <li>It's <a href=\"https://www.telecompaper.com/news/ginx-esports-tv-launches-on-cellcom-israels-iptv-service--1201937\" target=\"_blank\">added Ginx Esports</a> to its IPTV service, adding to a growing phenomenon of videogaming for broadcast. Ginx targets the key demographic of Israeli millennials, the company says.</li>    <li>Ginx is available in more than 45M homes in 80 countries and runs 24 hours.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3276373\" data-linked=\"Cellcom adds Ginx Esports to TV service\" data-tweet=\"$CEL - Cellcom adds Ginx Esports to TV service https://seekingalpha.com/news/3276373-cellcom-adds-ginx-esports-to-tv-service?source=tweet\" data-url=\"https://seekingalpha.com/news/3276373-cellcom-adds-ginx-esports-to-tv-service\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:11 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276370\" data-ts=\"1498763097\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/THO\" target=\"_blank\">THO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276370-thor-industries-leads-rv-names-lower-after-off-wall-street-sell-recommendation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Thor Industries leads RV names lower after Off Wall Street sell recommendation</a></h4><ul><li>Citing expectations for U.S. RV sales to peak this year, Off Wall Street initiates coverage of Thor Industries (<a href='https://seekingalpha.com/symbol/THO' title='Thor Industries, Inc.'>THO</a> <font color='red'>-3%</font>) with a sell rating, and $75 price target (<font color='red'>30% downside</font>).</li><li>Winnebago (<a href='https://seekingalpha.com/symbol/WGO' title='Winnebago Industries, Inc.'>WGO</a> <font color='red'>-2.7%</font>), LCI Industries (<a href='https://seekingalpha.com/symbol/LCII' title='LCI Industries'>LCII</a> <font color='red'>-2.7%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3276370\" data-linked=\"Thor Industries leads RV names lower after Off Wall Street sell recommendation\" data-tweet=\"$THO $THO $WGO - Thor Industries leads RV names lower after Off Wall Street sell recommendation https://seekingalpha.com/news/3276370-thor-industries-leads-rv-names-lower-after-off-wall-street-sell-recommendation?source=tweet\" data-url=\"https://seekingalpha.com/news/3276370-thor-industries-leads-rv-names-lower-after-off-wall-street-sell-recommendation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276364\" data-ts=\"1498761949\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276364-technology-top-gainers-losers-of-2-45-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:45 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/AYI' title='Acuity Brands, Inc. &#40;Holding Company&#41;'>AYI</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/INOD' title='Innodata Inc.'>INOD</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/NCTY' title='The9 Limited'>NCTY</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/SHSP' title='SharpSpring, Inc.'>SHSP</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/INPX' title='Inpixon'>INPX</a> <font color='red'>-48%</font>. <a href='https://seekingalpha.com/symbol/MRAM' title='Everspin Technologies'>MRAM</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/PI' title='Impinj, Inc.'>PI</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/BRKS' title='Brooks Automation, Inc.'>BRKS</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/EMKR' title='EMCORE Corporation'>EMKR</a> <font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3276364\" data-linked=\"Technology - Top Gainers / Losers as of 2:45 pm\" data-tweet=\"$AYI $INOD $NCTY - Technology - Top Gainers / Losers as of 2:45 pm https://seekingalpha.com/news/3276364-technology-top-gainers-losers-of-2-45-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3276364-technology-top-gainers-losers-of-2-45-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:45 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276360\" data-ts=\"1498760830\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMFW\" target=\"_blank\">AMFW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276360-amec-foster-wheeler-to-keep-european-nuclear-business\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amec Foster Wheeler to keep European nuclear business</a></h4><ul>     <li>Amec Foster Wheeler (<a href='https://seekingalpha.com/symbol/AMFW' title='Amec Foster Wheeler plc'>AMFW</a> <font color='red'>-2.3%</font>) says it will <a href=\"https://seekingalpha.com/filing/3609584\" target=\"_blank\">retain its European nuclear business</a> but go ahead with the planned sale of its North American nuclear operations.</li>     <li>AMFW says it made the decision after consulting the board of Wood Group (<a href='https://seekingalpha.com/symbol/WDGJF' title='Wood Group &#40;John&#41; Plc.'>OTCPK:WDGJF</a>), which is <a href=\"https://seekingalpha.com/news/3250541-amec-foster-wheeler-agrees-takeover-offer-john-wood\" target=\"_blank\">buying the company</a> for &pound;2.23B.</li>     <li>AMFW's North American nuclear operations contributed revenue of &pound;83M and trading profit of &pound;1M of trading profit in FY 2016.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3276360\" data-linked=\"Amec Foster Wheeler to keep European nuclear business\" data-tweet=\"$AMFW $AMFW $WDGJF - Amec Foster Wheeler to keep European nuclear business https://seekingalpha.com/news/3276360-amec-foster-wheeler-to-keep-european-nuclear-business?source=tweet\" data-url=\"https://seekingalpha.com/news/3276360-amec-foster-wheeler-to-keep-european-nuclear-business\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:27 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276357\" data-ts=\"1498759316\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276357-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/RCON' title='Recon Technology, Ltd.'>RCON</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/ERN' title='Erin Energy Corp.'>ERN</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/HK' title='Halcon Resources Corporation'>HK</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/PACD' title='Pacific Drilling SA'>PACD</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/NR' title='Newpark Resources Inc.'>NR</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ALO' title='Alio Gold Inc'>ALO</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/WMLP-OLD' title='Westmoreland Resource Partners, LP'>WMLP-OLD</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/XCO' title='EXCO Resources, Inc.'>XCO</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/NG' title='NovaGold Resources, Inc'>NG</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/NAK' title='Northern Dynasty Minerals Ltd'>NAK</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3276357\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$RCON $ERN $HKRS - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3276357-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3276357-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276351\" data-ts=\"1498757413\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRTA\" target=\"_blank\">PRTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276351-prothena-claws-back-from-bearish-report-from-short-seller-down-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Prothena claws back from bearish report from short seller, down 3%</a></h4><ul><li>Prothena (<a href='https://seekingalpha.com/symbol/PRTA' title='Prothena Corp plc'>PRTA</a> <font color='red'>-2.5%</font>) has recouped most of its earlier sell-off, down&nbsp;<font color='red'>10%&nbsp;</font>early in the session, after short seller Muddy Waters disclosed a position. Investors appear to be doubting Muddy's analysis supporting its perception of questionable efficacy.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3276308-prothena-slumps-4-percent-muddy-waters-short-position-doubts-efficacy-lead-product-candidate\" target=\"_blank\">Prothena slumps 4% on Muddy Waters short position, doubts efficacy of lead product candidate</a> (June 29)</li></ul><div class=\"tiny-share-widget\" data-id=\"3276351\" data-linked=\"Prothena claws back from bearish report from short seller, down 3%\" data-tweet=\"$PRTA - Prothena claws back from bearish report from short seller, down 3% https://seekingalpha.com/news/3276351-prothena-claws-back-from-bearish-report-from-short-seller-down-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3276351-prothena-claws-back-from-bearish-report-from-short-seller-down-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276347\" data-ts=\"1498755631\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276347-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/FSAM' title='Fifth Street Asset Management Inc.A'>OTCPK:FSAM</a> <font color='green'>+61%</font>. FSC <font color='green'>+8%</font>.<a href='https://seekingalpha.com/symbol/MFIN' title='Medallion Financial'>MFIN</a> <font color='green'>+7%</font>. FSFR <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/ATLC' title='Atlanticus Holdings Corp.'>ATLC</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/DOC' title='Physicians Realty Trust'>DOC</a> <font color='red'>-6%</font>. WMIH <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/SGLB' title='Sigma Labs, Inc.'>SGLB</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3276347\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$FSAM $OCSL $MFIN - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3276347-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3276347-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276345\" data-ts=\"1498755305\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OAK\" target=\"_blank\">OAK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276345-fifth-street-vehicles-jump-on-report-oaktree-is-buying-manager\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fifth Street vehicles jump on report Oaktree is buying manager</a></h4><ul><li>Oaktree (NYSE:<a href='https://seekingalpha.com/symbol/OAK' title='Oaktree Capital Group'>OAK</a>) is nearing a $350M buyout of Fifth Street Asset Management (<a href='https://seekingalpha.com/symbol/FSAM' title='Fifth Street Asset Management Inc.A'>OTCPK:FSAM</a> <font color='green'>+48.7%</font>), <a href=\"https://seekingalpha.com/news/3276108-new-aig-boss-backs-buybacks\" target=\"_blank\">according to Dow Jones</a>.</li><li>Fifth Street Finance (FSC <font color='green'>+8.7%</font>), Fifth Street Floating Rate (FSFR <font color='green'>+4.9%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3276345\" data-linked=\"Fifth Street vehicles jump on report Oaktree is buying manager\" data-tweet=\"$OAK $OAK $FSAM - Fifth Street vehicles jump on report Oaktree is buying manager https://seekingalpha.com/news/3276345-fifth-street-vehicles-jump-on-report-oaktree-is-buying-manager?source=tweet\" data-url=\"https://seekingalpha.com/news/3276345-fifth-street-vehicles-jump-on-report-oaktree-is-buying-manager\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276344\" data-ts=\"1498755128\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRNE\" target=\"_blank\">SRNE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276344-fda-oks-sorrentos-ind-for-non-opioid-pain-candidate-resiniferatoxin-clinical-trial-in-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Sorrento&#39;s IND for non-opioid pain candidate resiniferatoxin, clinical trial in cancer pain planned; shares up 3%</a></h4><ul><li>The FDA has <a href=\"https://seekingalpha.com/pr/16876221-sorrento-therapeutics-announced-fda-authorization-ind-commence-clinical-trial-rtx-intractable\" target=\"_blank\">signed off</a> on Sorrento Therapeutics' (<a href='https://seekingalpha.com/symbol/SRNE' title='Sorrento Therapeutics, Inc.'>SRNE</a> <font color='green'>+2.5%</font>) Investigational New Drug Application &#40;IND&#41; for resiniferatoxin, a non-opioid TRPV1 agonist for the potential treatment of chronic pain. The company intends to promptly launch a Phase 1b study in cancer patients with intractable pain, an Orphan Drug designation.</li><li>Resiniferatoxin, administered via epidural injection, directly interacts with nerve cells in the spine without affecting normal sensation or muscle function. Preliminary results from a Phase 1 study at NIH showed clinically meaningful reductions in pain and a reduced dependence on opioids.</li></ul><div class=\"tiny-share-widget\" data-id=\"3276344\" data-linked=\"FDA OKs Sorrento&#39;s IND for non-opioid pain candidate resiniferatoxin, clinical trial in cancer pain planned; shares up 3%\" data-tweet=\"$SRNE - FDA OKs Sorrento&#39;s IND for non-opioid pain candidate resiniferatoxin, clinical trial in cancer pain planned; shares up 3% https://seekingalpha.com/news/3276344-fda-oks-sorrentos-ind-for-non-opioid-pain-candidate-resiniferatoxin-clinical-trial-in-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3276344-fda-oks-sorrentos-ind-for-non-opioid-pain-candidate-resiniferatoxin-clinical-trial-in-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276343\" data-ts=\"1498754935\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GBRRF\" target=\"_blank\">GBRRF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276343-gabriel-resources-to-seek-4_4b-in-damages-from-romania\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gabriel Resources to seek $4.4B in damages from Romania</a></h4><ul>     <li>Gabriel Resources (<a href='https://seekingalpha.com/symbol/GBRRF' title='Gabriel Resources Ltd.'>OTCPK:GBRRF</a> <font color='red'>-4%</font>) will <a href=\"https://www.theglobeandmail.com/report-on-business/industry-news/energy-and-resources/gabriel-resources-to-seek-44-billion-in-damages-from-romania/article35497728/\" target=\"_blank\">seek $4.4B in damages</a> from Romania for losses related to its long-stalled Rosia Montana gold mine project in a claim that the Canadian miner plans to file tomorrow with the World Bank's settlement arm.</li>     <li>Gabriel, which has spent two decades trying to build the mine, says Romania's government has unlawfully blocked permits, disregarded existing license rights and ignored all requests for conciliation and negotiation.</li>     <li>The project was expected to produce 500K oz./year of gold over 16 years of operation, making it Europe&rsquo;s largest gold mine; the company once was worth more than C$2.7B but its value has collapsed as the chance of the mine ever being built evaporated.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3276343\" data-linked=\"Gabriel Resources to seek $4.4B in damages from Romania\" data-tweet=\"$GBRRF - Gabriel Resources to seek $4.4B in damages from Romania https://seekingalpha.com/news/3276343-gabriel-resources-to-seek-4_4b-in-damages-from-romania?source=tweet\" data-url=\"https://seekingalpha.com/news/3276343-gabriel-resources-to-seek-4_4b-in-damages-from-romania\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:48 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276342\" data-ts=\"1498754869\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276342-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SPEX' title='Spherix Incorporated'>SPEX</a> <font color='green'>+98%</font>. <a href='https://seekingalpha.com/symbol/NXTD' title='NXT-ID Inc.'>NXTD</a> <font color='green'>+38%</font>. <a href='https://seekingalpha.com/symbol/FSAM' title='Fifth Street Asset Management Inc.A'>OTCPK:FSAM</a> <font color='green'>+39%</font>. <a href='https://seekingalpha.com/symbol/OBSV' title='ObsEva'>OBSV</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/PCYO' title='Pure Cycle Corporation'>PCYO</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/BSET' title='Bassett Furniture Industries, Incorporated'>BSET</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/GTXI' title='GTx, Inc.'>GTXI</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/NYMX' title='Nymox Pharmaceutical Corporation'>NYMX</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/CADC' title='China Advanced Construction Materials Group, Inc.'>CADC</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/ERN' title='Erin Energy Corp.'>ERN</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/INPX' title='Inpixon'>INPX</a> <font color='red'>-47%</font>. <a href='https://seekingalpha.com/symbol/RAD' title='Rite Aid Corporation'>RAD</a> <font color='red'>-29%</font>. <a href='https://seekingalpha.com/symbol/FRED' title='Fred&#39;s, Inc.'>FRED</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/ALO' title='Alio Gold Inc'>ALO</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/AIRI' title='Air Industries Group, Inc.'>AIRI</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/BIOS' title='BioScrip, Inc.'>BIOS</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a> <font color='red'>-11%</font>. PBMD <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/WMLP-OLD' title='Westmoreland Resource Partners, LP'>WMLP-OLD</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/BLCM' title='Bellicum Pharmaceuticals'>BLCM</a> <font color='red'>-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3276342\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$SPEX $NXTD $FSAM - Midday Gainers / Losers https://seekingalpha.com/news/3276342-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3276342-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:47 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276340\" data-ts=\"1498754369\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWTR\" target=\"_blank\">TWTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276340-twitter-to-offer-streaming-coverage-of-comic-con\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Twitter to offer streaming coverage of Comic-Con</a></h4><ul>     <li>After a run at live-streaming the gamer-centric Electronic Entertainment Expo, Twitter (<a href=\"http://seekingalpha.com/symbol/TWTR\" target=\"_blank\">TWTR</a> <font color='red'>-2.6%</font>) will try its hand at a bigger-money gaming/entertainment gathering: Comic-Con San Diego.</li>    <li>The company is partnering with IGN to <a href=\"http://www.marketwatch.com/story/twitter-will-partner-with-ign-to-live-stream-san-diego-comic-con-2017-06-29\" target=\"_blank\">live-stream Comic-Con</a>, which now breaks major news on film, television and the comic-book industry each year.</li>    <li>Twitter's E3 coverage drew an average of 2.6M unique viewers per day.</li>    <li>IGN will host and produce 13 hours of coverage at Comic-Con, beginning July 19.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3276340\" data-linked=\"Twitter to offer streaming coverage of Comic-Con\" data-tweet=\"$TWTR - Twitter to offer streaming coverage of Comic-Con https://seekingalpha.com/news/3276340-twitter-to-offer-streaming-coverage-of-comic-con?source=tweet\" data-url=\"https://seekingalpha.com/news/3276340-twitter-to-offer-streaming-coverage-of-comic-con\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276333\" data-ts=\"1498752956\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALRN\" target=\"_blank\">ALRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276333-aileron-picks-bad-day-for-debut-shares-down-18\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aileron picks bad day for debut, shares down 18%</a></h4><ul><li>The market sell-off engulfs IPO Aileron Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ALRN' title='Aileron Therapeutics'>ALRN</a>). Shares are down 18% from the offer price of $15 on turnover of 843K shares.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3274832-aileron-therapeutics-deck-ipo\" target=\"_blank\">Aileron Therapeutics on deck of IPO</a> (June 21)</li></ul><div class=\"tiny-share-widget\" data-id=\"3276333\" data-linked=\"Aileron picks bad day for debut, shares down 18%\" data-tweet=\"$ALRN - Aileron picks bad day for debut, shares down 18% https://seekingalpha.com/news/3276333-aileron-picks-bad-day-for-debut-shares-down-18?source=tweet\" data-url=\"https://seekingalpha.com/news/3276333-aileron-picks-bad-day-for-debut-shares-down-18\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276332\" data-ts=\"1498752803\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HR\" target=\"_blank\">HR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276332-health-care-reits-lower-physicians-realty-purchases-mulled\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Health care REITs lower; Physicians Realty purchases mulled</a></h4><ul><li>Physicians Realty Trust <a href=\"https://seekingalpha.com/news/3276331-physicians-realty-trust-minus-5-percent-tenant-issues-acquisitions-capital-raise-news\" target=\"_blank\">last night announced</a> another $735M of purchases.</li><li>Noting that DOC is now paying sub-5% cap rates for properties - dilutive to earnings and NAV - Jefferies analyst Tayo Okusanya tells Bloomberg there's concern MOB-focused companies can no longer do accretive deals for quality assets.</li><li>Healthcare Realty Trust (<a href='https://seekingalpha.com/symbol/HR' title='Healthcare Realty Trust Inc.'>HR</a> <font color='red'>-3.5%</font>), Senior Housing Properties (<a href='https://seekingalpha.com/symbol/SNH' title='Senior Housing Properties Trust'>SNH</a> <font color='red'>-3%</font>), Omega Healthcare (<a href='https://seekingalpha.com/symbol/OHI' title='Omega Healthcare Investors, Inc'>OHI</a> <font color='red'>-3.5%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3276332\" data-linked=\"Health care REITs lower; Physicians Realty purchases mulled\" data-tweet=\"$HR $HR $SNH - Health care REITs lower; Physicians Realty purchases mulled https://seekingalpha.com/news/3276332-health-care-reits-lower-physicians-realty-purchases-mulled?source=tweet\" data-url=\"https://seekingalpha.com/news/3276332-health-care-reits-lower-physicians-realty-purchases-mulled\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>38&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276331\" data-ts=\"1498752322\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DOC\" target=\"_blank\">DOC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276331-physicians-realty-trustminus-5-tenant-issues-acquisitions-capital-raise-all-in-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Physicians Realty Trust -5%; tenant issues, acquisitions, capital raise all in the news</a></h4><ul><li>The tenant of the 162K square foot Kennewick medical office building <a href=\"https://seekingalpha.com/pr/16875123-physicians-realty-trust-announces-735_0-million-executed-purchase-sale-agreements-including\" target=\"_blank\">has stopped paying rent</a>, and future payments aren't looking good. All told, it's expected to cost <a href='https://seekingalpha.com/symbol/DOC' title='Physicians Realty Trust'>DOC</a> $0.02 per share of normalized FFO in Q2.</li><li>In addition, the timing of the capital raises and putting that money to work is expected to cut $0.03 from normalized FFO in Q2.</li><li>The company has <a href=\"https://seekingalpha.com/pr/16875123-physicians-realty-trust-announces-735_0-million-executed-purchase-sale-agreements-including\" target=\"_blank\">also inked another</a> $735M of deals, including the Baylor Charles A. Sammons Cancer Center.</li><li>DOC <a href=\"https://seekingalpha.com/pr/16875351-physicians-realty-trust-announces-pricing-public-offering-20000-000-common-shares\" target=\"_blank\">also sold 20M shares</a> overnight at a price of $20.40 each. The underwriters have an option to buy another 3M shares at that price.</li><li>The stock's<font color='red'> lower by 5.05%</font>&nbsp;to $20.30.</li></ul><div class=\"tiny-share-widget\" data-id=\"3276331\" data-linked=\"Physicians Realty Trust -5%; tenant issues, acquisitions, capital raise all in the news\" data-tweet=\"$DOC - Physicians Realty Trust -5%; tenant issues, acquisitions, capital raise all in the news https://seekingalpha.com/news/3276331-physicians-realty-trustminus-5-tenant-issues-acquisitions-capital-raise-all-in-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3276331-physicians-realty-trustminus-5-tenant-issues-acquisitions-capital-raise-all-in-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276330\" data-ts=\"1498752039\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276330-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> SCSS <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/BSET' title='Bassett Furniture Industries, Incorporated'>BSET</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/WATT' title='Energous Corp.'>WATT</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/ADOM' title='ADOMANI, Inc.'>ADOM</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/FOSL' title='Fossil, Inc.'>FOSL</a> <font color='green'>+7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3276330\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$SNBR $BSET $WATT - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3276330-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3276330-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276326\" data-ts=\"1498751714\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMMP\" target=\"_blank\">IMMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276326-prima-biomed-prices-direct-ads-offering-1_90-shares-down-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Prima BioMed prices direct ADS offering at $1.90; shares down 5%</a></h4><ul><li>Thinly traded nano cap Prima BioMed (PBMD <font color='red'>-5.4%</font>) slips on 40% higher volume, albeit on only 50K shares, in response to its <a href=\"https://seekingalpha.com/pr/16876157-prima-biomed-announces-pricing-us-5_0-million-registered-direct-offering-american-depositary\" target=\"_blank\">direct offering</a> of 2,631,268 American Depositary Shares (ADSs) to accredited investors at $1.90 per ADS. The offering includes 5 1/2-year warrants to purchase up to 1,973,451 ADSs at $2.50. Closing date is July 5.</li><li>Net proceeds will fund the clinical development of IMP321, preclinical work on IMP761 and general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3276326\" data-linked=\"Prima BioMed prices direct ADS offering at $1.90; shares down 5%\" data-tweet=\"$IMMP - Prima BioMed prices direct ADS offering at $1.90; shares down 5% https://seekingalpha.com/news/3276326-prima-biomed-prices-direct-ads-offering-1_90-shares-down-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3276326-prima-biomed-prices-direct-ads-offering-1_90-shares-down-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:55 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276323\" data-ts=\"1498751555\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SGBX\" target=\"_blank\">SGBX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276323-sg-blocks-up-2_5-on-announcing-rooftop-venue-project-leading-national-supermarket-chain\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SG Blocks up 2.5% on announcing rooftop venue project with leading national supermarket chain</a></h4><ul>     <li>SG Blocks (<a href='https://seekingalpha.com/symbol/SGBX' title='SG Blocks'>SGBX</a> <font color='green'>+2.5%</font>)&nbsp;<a href=\"https://seekingalpha.com/pr/16876057-sg-blocks-announces-rooftop-venue-project-leading-national-supermarket-chain\" target=\"_blank\">announced</a> that it is working with one of the country's largest national supermarket chains to deliver a rooftop venue for one of its locations. The project is expected to be completed and delivered in the Q317.</li>     <li>CEO Paul Galvin: &nbsp;\"Organizations across the country are increasingly choosing our container-based method of construction as the foremost solution to their building and development needs, We are pleased to offer a sustainable, reliable and cost-efficient product.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3276323\" data-linked=\"SG Blocks up 2.5% on announcing rooftop venue project with leading national supermarket chain\" data-tweet=\"$SGBX $SGBXQ - SG Blocks up 2.5% on announcing rooftop venue project with leading national supermarket chain https://seekingalpha.com/news/3276323-sg-blocks-up-2_5-on-announcing-rooftop-venue-project-leading-national-supermarket-chain?source=tweet\" data-url=\"https://seekingalpha.com/news/3276323-sg-blocks-up-2_5-on-announcing-rooftop-venue-project-leading-national-supermarket-chain\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276317\" data-ts=\"1498749268\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276317-banks-rally-tech-leads-declines-in-major-averages\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Banks rally, but tech leads declines in major averages</a></h4><ul><li>Banking indices are&nbsp;<font color='green'>up 2%</font>&nbsp;following <a href=\"https://seekingalpha.com/news/3276231-financial-sector-set-another-big-day-ccar\" target=\"_blank\">pleasing CCAR results </a>and another surge higher in interest rates, but most everything else is in the red today.</li><li>The Nasdaq continues its rollercoaster ride this week - down more than 1% on Tuesday, up more than 1% yesterday, and&nbsp;<font color='red'>down 1.35%</font>&nbsp;this session.</li><li>The S&amp;P 500 is&nbsp;<font color='red'>off 0.5%</font>, and DJIA&nbsp;<font color='red'>0.3%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3276317\" data-linked=\"Banks rally, but tech leads declines in major averages\" data-tweet=\"Banks rally, but tech leads declines in major averages https://seekingalpha.com/news/3276317-banks-rally-tech-leads-declines-in-major-averages?source=tweet\" data-url=\"https://seekingalpha.com/news/3276317-banks-rally-tech-leads-declines-in-major-averages\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276316\" data-ts=\"1498748626\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNBR\" target=\"_blank\">SNBR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276316-big-gains-for-mattress-stocks-on-m-speculation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Big gains for mattress stocks on M&amp;A speculation</a></h4><ul> <li>Select Comfort (SCSS <font color='green'>+13.5%</font>) and Tempur Sealy (<a href='https://seekingalpha.com/symbol/TPX' title='Tempur Sealy International Inc.'>TPX</a> <font color='green'>+7.3%</font>) rocket higher amid speculation from Dealreporter that something might be brewing in the mattress space.</li> <li>Tempur Sealy entered into a standstill agreement with director Usman Nabi earlier this week.</li> <li><a href=\"https://seekingalpha.com/filing/3608506\" target=\"_blank\">SEC Form 8-K</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3276316\" data-linked=\"Big gains for mattress stocks on M&amp;A speculation\" data-tweet=\"$SNBR $SNBR $TPX - Big gains for mattress stocks on M&amp;A speculation https://seekingalpha.com/news/3276316-big-gains-for-mattress-stocks-on-m-speculation?source=tweet\" data-url=\"https://seekingalpha.com/news/3276316-big-gains-for-mattress-stocks-on-m-speculation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276284\" data-ts=\"1498748481\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276284-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/OBSV' title='ObsEva'>OBSV</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/NBY' title='NovaBay Pharmaceuticals, Inc.'>NBY</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/SBBP' title='Strongbridge Biopharma'>SBBP</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/CASM' title='CAS Medical Systems, Inc.'>CASM</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/NYMX' title='Nymox Pharmaceutical Corporation'>NYMX</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/BLCM' title='Bellicum Pharmaceuticals'>BLCM</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/CASC' title='Cascadian Therapeutics, Inc'>CASC</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/HTGM' title='HTG Molecular Diagnostics'>HTGM</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/MACK' title='Merrimack Pharmaceuticals'>MACK</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/AKBA' title='Akebia Therapeutics, Inc.'>AKBA</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3276284\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$OBSV $NBY $SBBP - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3276284-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3276284-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276310\" data-ts=\"1498747725\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APC\" target=\"_blank\">APC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276310-anadarko-petroleumplus-3-susquehanna-makes-positive-valuation-call\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Anadarko Petroleum +3% as Susquehanna makes positive valuation call</a></h4><ul>     <li>Anadarko Petroleum (<a href='https://seekingalpha.com/symbol/APC' title='Anadarko Petroleum Corporation'>APC</a> <font color='green'>+2.9%</font>) enjoys strong gains in early trading after Susquehanna initiates coverage with a <a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Susquehanna+Starts+Anadarko+Petroleum+%28APC%29+at+Positive/13056911.html\" target=\"_blank\">Positive rating</a> and a $60 price target, citing valuation.</li>     <li>While regulatory uncertainty in Colorado could provide near-term headwinds, the firm sees APC as attractively priced and offering a positive risk/reward in light of recent weakness.</li>     <li>APC hit an intraday 52-week low yesterday of $43.45 and have lost 35% YTD; shares have been particularly weak since the company was linked to a <a href=\"https://seekingalpha.com/news/3262894-anadarko-petro-minus-7_5-percent-worries-grow-fatal-gas-blast-linked-well\" target=\"_blank\">fatal Colorado home explosion incident</a> near one of its old wells.</li></ul><div class=\"tiny-share-widget\" data-id=\"3276310\" data-linked=\"Anadarko Petroleum +3% as Susquehanna makes positive valuation call\" data-tweet=\"$APC - Anadarko Petroleum +3% as Susquehanna makes positive valuation call https://seekingalpha.com/news/3276310-anadarko-petroleumplus-3-susquehanna-makes-positive-valuation-call?source=tweet\" data-url=\"https://seekingalpha.com/news/3276310-anadarko-petroleumplus-3-susquehanna-makes-positive-valuation-call\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276308\" data-ts=\"1498747533\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRTA\" target=\"_blank\">PRTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276308-prothena-slumps-4-on-muddy-waters-short-position-doubts-efficacy-of-lead-product-candidate\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Prothena slumps 4% on Muddy Waters short position, doubts efficacy of lead product candidate</a></h4><ul><li>Thinly traded Prothena (<a href='https://seekingalpha.com/symbol/PRTA' title='Prothena Corp plc'>PRTA</a> <font color='red'>-3.9%</font>) is down on double normal volume on the <a href=\"https://www.streetinsider.com/Corporate+News/Muddy+Waters+is+Short+Prothena+Corp.+%28PRTA%29/13057658.html\" target=\"_blank\">news</a> that short seller Muddy Waters has established a position based on doubts with the efficacy of lead product candidate NEOD001, a monoclonal antibody for the potential treatment of systemic amyloidosis.</li><li><strong>Update</strong>: In its <a href=\"http://www.muddywatersresearch.com/research/prta/mw-is-short-prothena/\" target=\"_blank\">full report,</a> MW says it believes perceived responses to NEOD001 are due to previous plasma cell-directed therapy, adding that its proposed mechanism of action is unproven. It also believes the Street's consensus peak sales of $1.5B is unrealistic due to the small amyloidosis patient population and the risk that many payers will not reimburse for the drug.</li></ul><div class=\"tiny-share-widget\" data-id=\"3276308\" data-linked=\"Prothena slumps 4% on Muddy Waters short position, doubts efficacy of lead product candidate\" data-tweet=\"$PRTA - Prothena slumps 4% on Muddy Waters short position, doubts efficacy of lead product candidate https://seekingalpha.com/news/3276308-prothena-slumps-4-on-muddy-waters-short-position-doubts-efficacy-of-lead-product-candidate?source=tweet\" data-url=\"https://seekingalpha.com/news/3276308-prothena-slumps-4-on-muddy-waters-short-position-doubts-efficacy-of-lead-product-candidate\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276302\" data-ts=\"1498746614\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276302-natural-gas-inventory-build-comes-in-lower-expected\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Natural gas inventory build comes in lower than expected</a></h4><ul>     <li><a href=\"http://ir.eia.gov/ngs/ngs.html\" target=\"_blank\">EIA Natural Gas Inventory:</a> <strong>+46 Bcf</strong> vs. +52 Bcf consensus, +61 Bcf last week.</li><li>Futures&nbsp;<font color='red'>-0.74%</font>&nbsp;to $3.071.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a>, <a href='https://seekingalpha.com/symbol/DGAZ' title='VelocityShares 3x Inverse Natural Gas ETN'>DGAZ</a>, <a href='https://seekingalpha.com/symbol/UGAZ' title='VelocityShares 3x Long Natural Gas ETN'>UGAZ</a>, <a href='https://seekingalpha.com/symbol/BOIL' title='ProShares Ultra Bloomberg Natural Gas ETF'>BOIL</a>, <a href='https://seekingalpha.com/symbol/GAZ' title='iPath DJ-UBS Natural Gas Total Return Sub-Index ETN'>GAZ</a>, <a href='https://seekingalpha.com/symbol/KOLD' title='ProShares UltraShort Bloomberg Natural Gas ETF'>KOLD</a>, <a href='https://seekingalpha.com/symbol/UNL' title='The United States 12 Month Natural Gas ETF, LP'>UNL</a>,<a href='https://seekingalpha.com/symbol/DCNG' title='iPath Pure Beta Seasonal Natural Gas ETN'>DCNG</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3276302\" data-linked=\"Natural gas inventory build comes in lower than expected\" data-tweet=\"$UNG $DGAZ $UGAZ - Natural gas inventory build comes in lower than expected https://seekingalpha.com/news/3276302-natural-gas-inventory-build-comes-in-lower-expected?source=tweet\" data-url=\"https://seekingalpha.com/news/3276302-natural-gas-inventory-build-comes-in-lower-expected\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276297\" data-ts=\"1498745966\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BSET\" target=\"_blank\">BSET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276297-on-bassett-furnitures-q2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Bassett Furniture&#39;s Q2</a></h4><ul><li>Bassett Furniture (<a href='https://seekingalpha.com/symbol/BSET' title='Bassett Furniture Industries, Incorporated'>BSET</a> <font color='green'>+12.5%</font>)&nbsp;reports comparable-store sales rose 6.3% in <a href=\"https://seekingalpha.com/pr/16875915-bassett-announces-fiscal-second-quarter-results\" target=\"_blank\">Q2</a>.</li><li>Wholesale segment revenue increased 4% to $62.3M.</li><li>Retail segment revenue up 8.4% to $67.1M.</li><li>Logistical services revenue grew 3.4% to $24.6M.</li><li>The gross margin rate improved 40 bps to 60.6%.</li><li>Operating margin rate expanded 120 bps to 6.7%.</li><li>Store Count +2 Q/Q to 91.</li></ul><div class=\"tiny-share-widget\" data-id=\"3276297\" data-linked=\"More on Bassett Furniture&#39;s Q2\" data-tweet=\"$BSET - More on Bassett Furniture&#39;s Q2 https://seekingalpha.com/news/3276297-on-bassett-furnitures-q2?source=tweet\" data-url=\"https://seekingalpha.com/news/3276297-on-bassett-furnitures-q2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276292\" data-ts=\"1498745384\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EDR\" target=\"_blank\">EDR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276292-education-realty-down-2_8-after-citi-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Education Realty down 2.8% after Citi downgrade</a></h4><ul><li>Education Realty Trust (<a href='https://seekingalpha.com/symbol/EDR' title='EdR'>EDR</a> <font color='red'>-2.8%</font>) &nbsp;could face time \"in the penalty box\" after a delay in its Oklahoma State development until next year, says Citi analyst Michael Bilerman, downgrading to Neutral.</li><li>His price target of $41 compares to the current $39.10.</li></ul><div class=\"tiny-share-widget\" data-id=\"3276292\" data-linked=\"Education Realty down 2.8% after Citi downgrade\" data-tweet=\"$EDR $EDR-OLD - Education Realty down 2.8% after Citi downgrade https://seekingalpha.com/news/3276292-education-realty-down-2_8-after-citi-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3276292-education-realty-down-2_8-after-citi-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276290\" data-ts=\"1498745219\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EMKR\" target=\"_blank\">EMKR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276290-emcoreminus-4_8-b-riley-first-to-move-to-neutral\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Emcore -4.8% as B. Riley first to move to Neutral</a></h4><ul>   <li>Optical component maker Emcore (NASDAQ:<a href='https://seekingalpha.com/symbol/EMKR' title='EMCORE Corporation'>EMKR</a>) has <font color='red'>slid 4.8%</font> following a downgrade to Neutral at B. Riley, departing from a unanimous chorus of analysts at Buy.</li>    <li>The firm has a price target of $12 on the shares, implying just 4.3% upside from yesterday's close.</li>    <li>Peers that usually move based on vicissitudes of Chinese demand are trading lower as well: <a href='https://seekingalpha.com/symbol/AAOI' title='Applied Optoelectronics, Inc.'>AAOI</a> <font color='red'>-2.5%</font>; <a href='https://seekingalpha.com/symbol/NPTN' title='NeoPhotonics Corporation'>NPTN</a> <font color='red'>-2.3%</font>; <a href='https://seekingalpha.com/symbol/FNSR' title='Finisar Corporation'>FNSR</a> <font color='red'>-1.7%</font>; <a href='https://seekingalpha.com/symbol/OCLR' title='Oclaro, Inc.'>OCLR</a> <font color='red'>-1.4%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3276290\" data-linked=\"Emcore -4.8% as B. Riley first to move to Neutral\" data-tweet=\"$EMKR $EMKR $AAOI - Emcore -4.8% as B. Riley first to move to Neutral https://seekingalpha.com/news/3276290-emcoreminus-4_8-b-riley-first-to-move-to-neutral?source=tweet\" data-url=\"https://seekingalpha.com/news/3276290-emcoreminus-4_8-b-riley-first-to-move-to-neutral\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276279\" data-ts=\"1498743845\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LULU\" target=\"_blank\">LULU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276279-lululemon-rallies-after-insider-buying\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lululemon rallies after insider buying</a></h4><ul> <li>Lululemon (<a href='https://seekingalpha.com/symbol/LULU' title='Lululemon Athletica Inc.'>LULU</a> <font color='green'>+4.5%</font>) breaks higher after some insider buying is reported.</li> <li>Chairman Glenn Murphy picked up 100K shares in range of $55.48 to $55.50.</li> <li>The rally in LULU&nbsp;today follows some go-private chatter yesterday and has shares threatening to crest $60 for the first time since late March.</li> <li><a href=\"https://seekingalpha.com/filing/3608242\" target=\"_blank\">SEC Form 4</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3276279\" data-linked=\"Lululemon rallies after insider buying\" data-tweet=\"$LULU - Lululemon rallies after insider buying https://seekingalpha.com/news/3276279-lululemon-rallies-after-insider-buying?source=tweet\" data-url=\"https://seekingalpha.com/news/3276279-lululemon-rallies-after-insider-buying\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276277\" data-ts=\"1498743242\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276277-bond-rout-gets-rolling-central-banks-threaten\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bond rout gets rolling as central banks threaten</a></h4><ul><li>It's a <a href=\"https://www.wsj.com/articles/global-government-bond-prices-fall-dollar-sags-1498726872\" target=\"_blank\">third straight day of big price declines </a>(yields higher) for bond prices as the hawkishness spreads from the Fed to the Bank of Canada, the ECB, and the Bank of England.</li><li>The 10-year U.S. Treasury yield is up another six basis points to 2.28% - it stood near 2.10% about 72 hours ago. The German 10-year Bund yield is higher by another 8 basis points to 0.454%; Italy up 12 bps, Spain up 10 bps, and the U.K. up 7 bps.</li><li>Some say the move is just getting started, noting the 10-year Treasury yield is still less than one percentage point higher than an all-time low of 1.366% hit last July. Bulls say structural changes - insurance companies and pensioners needing safe yield - mean plenty of buyers are standing ready.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3276013-western-central-banks-threaten-hit-brakes\" target=\"_blank\">Western central banks threaten to hit the brakes</a> (June 28)</li><li><a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a>&nbsp;<font color='red'>-1.2%</font>, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a>&nbsp;<font color='green'>+2.4%</font></li><li>ETFs: <a href='https://seekingalpha.com/symbol/AGG' title='iShares Core Total U.S. Bond Market ETF'>AGG</a>, <a href='https://seekingalpha.com/symbol/BND' title='Vanguard Total Bond Market ETF'>BND</a>, <a href='https://seekingalpha.com/symbol/PTY' title='PIMCO Corporate&Income Opportunity Fund'>PTY</a>, <a href='https://seekingalpha.com/symbol/BOND' title='PIMCO Total Return ETF'>BOND</a>, <a href='https://seekingalpha.com/symbol/RCS' title='PIMCO Strategic Income Fund, Inc'>RCS</a>, <a href='https://seekingalpha.com/symbol/DBL' title='Doubleline Opportunistic Credit Fund'>DBL</a>, <a href='https://seekingalpha.com/symbol/BTZ' title='BlackRock Credit Allocation Income Trust IV'>BTZ</a>, <a href='https://seekingalpha.com/symbol/PCM' title='PCM Fund'>PCM</a>, <a href='https://seekingalpha.com/symbol/SCHZ' title='Schwab U.S. Aggregate Bond ETF'>SCHZ</a>, <a href='https://seekingalpha.com/symbol/BHK' title='BlackRock Core Bond Trust'>BHK</a>, <a href='https://seekingalpha.com/symbol/BNDS' title='SPDR Barclays Aggregate Bond ETF'>BNDS</a>, <a href='https://seekingalpha.com/symbol/JHI' title='John Hancock Investors Trust'>JHI</a>, <a href='https://seekingalpha.com/symbol/INC' title='iShares Edge U.S. Fixed Income Balanced Risk ETF'>INC</a>, <a href='https://seekingalpha.com/symbol/AGGY' title='WisdomTree Barclays Yield Enhanced U.S. Aggregate Bond ETF'>AGGY</a>, <a href='https://seekingalpha.com/symbol/JMM' title='Nuveen Multi-Market Income Fund, Inc.'>JMM</a>, <a href='https://seekingalpha.com/symbol/FBND' title='Fidelity Total Bond ETF'>FBND</a>, <a href='https://seekingalpha.com/symbol/ICB' title='Morgan Stanley Income Securities'>ICB</a>, <a href='https://seekingalpha.com/symbol/IUSB' title='iShares Core Total USD Bond Market ETF'>IUSB</a>, <a href='https://seekingalpha.com/symbol/VBF' title='Invesco Bond Fund'>VBF</a>, <a href='https://seekingalpha.com/symbol/TAI' title='Transamerica Income Shares'>TAI</a>, <a href='https://seekingalpha.com/symbol/PAI' title='Western Asset Income Fund'>PAI</a>, <a href='https://seekingalpha.com/symbol/SAGG' title='Direxion Daily Total Bond Market Bear 1x Shares ETF'>SAGG</a>, <a href='https://seekingalpha.com/symbol/GBF' title='iShares Government/Credit Bond ETF'>GBF</a>, <a href='https://seekingalpha.com/symbol/GTO' title='Guggenheim Total Return Bond ETF'>GTO</a>, <a href='https://seekingalpha.com/symbol/VBND' title='Vident Core U.S. Bond Strategy ETF'>VBND</a>, <a href='https://seekingalpha.com/symbol/AGGP' title='IQ Enhanced Core Plus Bond U.S. ETF'>AGGP</a>, <a href='https://seekingalpha.com/symbol/DWFI' title='SPDR Dorsey Wright Fixed Income Allocation ETF'>DWFI</a>, <a href='https://seekingalpha.com/symbol/AGGE' title='IQ Enhanced Core Bond U.S. ETF'>AGGE</a>, <a href='https://seekingalpha.com/symbol/HQBD' title='Hartford Quality Bond ETF'>HQBD</a>, <a href='https://seekingalpha.com/symbol/UBND' title='WisdomTree Western Asset Unconstrained Bond ETF'>UBND</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3276277\" data-linked=\"Bond rout gets rolling as central banks threaten\" data-tweet=\"$TLT $TBT $AGG - Bond rout gets rolling as central banks threaten https://seekingalpha.com/news/3276277-bond-rout-gets-rolling-central-banks-threaten?source=tweet\" data-url=\"https://seekingalpha.com/news/3276277-bond-rout-gets-rolling-central-banks-threaten\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276275\" data-ts=\"1498742901\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YY\" target=\"_blank\">YY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276275-yyminus-5-amid-chinese-government-video-dispute\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">YY -5% amid Chinese government video dispute</a></h4><ul>   <li>YY (NASDAQ:<a href='https://seekingalpha.com/symbol/YY' title='YY Inc.'>YY</a>) is <font color='red'>5% lower</font> premarket in U.S. trading as Chinese peers decline amid a crackdown on government-unapproved video content.</li>    <li>Weibo (NASDAQ:<a href='https://seekingalpha.com/symbol/WB' title='Weibo Corporation'>WB</a>) <a href=\"https://seekingalpha.com/news/3276219-weibo-will-block-unapproved-videos-chinese-government-crackdown\" target=\"_blank\">agreed to block</a> such content after being <a href=\"https://seekingalpha.com/news/3275038-chinese-social-media-tumbles-report-broadcast-crackdown\" target=\"_blank\">threatened with a shutdown</a> last week.</li>    <li>Moving premarket: <a href='https://seekingalpha.com/symbol/WB' title='Weibo Corporation'>WB</a> <font color='red'>-0.8%</font>; <a href='https://seekingalpha.com/symbol/BIDU' title='Baidu, Inc.'>BIDU</a> <font color='red'>-0.5%</font>. <a href='https://seekingalpha.com/symbol/FENG' title='Phoenix New Media Limited'>FENG</a> is flat, as is Weibo owner <a href='https://seekingalpha.com/symbol/SINA' title='Sina Corporation'>SINA</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3276275\" data-linked=\"YY -5% amid Chinese government video dispute\" data-tweet=\"$YY $YY $WB - YY -5% amid Chinese government video dispute https://seekingalpha.com/news/3276275-yyminus-5-amid-chinese-government-video-dispute?source=tweet\" data-url=\"https://seekingalpha.com/news/3276275-yyminus-5-amid-chinese-government-video-dispute\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276274\" data-ts=\"1498742898\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276274-teva-ahead-1-premarket-on-fda-acceptance-of-marketing-application-for-rituxan-biosimilar\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teva ahead 1% premarket on FDA acceptance of marketing application for Rituxan biosimilar</a></h4><ul><li>Teva Pharmaceutical Industries (NYSE:<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a>) is up&nbsp;<font color='green'>1%</font>&nbsp;premarket on light volume in response to the <a href=\"https://seekingalpha.com/pr/16875708-celltrion-teva-announce-u-s-fda-acceptance-biologics-license-application-proposed-biosimilar\" target=\"_blank\">news </a>that the FDA has accepted the Biologics License Application &#40;BLA&#41; from commercialization partner Celltrion seeking approval of CT-P10, a biosimilar to Biogen and Roche's Rituxan (rituximab). The agency's action date should be in Q1 2018.</li><li>The companies inked their agreement in October 2016. Teva has commercialization rights in the U.S. and Canada while Celltrion is responsible for completing all clinical development and regulatory activities.They will share profits.</li></ul><div class=\"tiny-share-widget\" data-id=\"3276274\" data-linked=\"Teva ahead 1% premarket on FDA acceptance of marketing application for Rituxan biosimilar\" data-tweet=\"$TEVA - Teva ahead 1% premarket on FDA acceptance of marketing application for Rituxan biosimilar https://seekingalpha.com/news/3276274-teva-ahead-1-premarket-on-fda-acceptance-of-marketing-application-for-rituxan-biosimilar?source=tweet\" data-url=\"https://seekingalpha.com/news/3276274-teva-ahead-1-premarket-on-fda-acceptance-of-marketing-application-for-rituxan-biosimilar\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276273\" data-ts=\"1498742591\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DHI\" target=\"_blank\">DHI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276273-d-r-horton-inks-merger-deal-forestar-group\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">D.R. Horton inks merger deal with Forestar Group</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/16875786-d-r-horton-forestar-announce-merger-agreement-create-leading-national-land-development\" target=\"_blank\">Under the terms</a>, D.R. Horton (NYSE:<a href='https://seekingalpha.com/symbol/DHI' title='D. R. Horton Inc.'>DHI</a>) will acquire 75% of the stock of Forestar Group (NYSE:<a href='https://seekingalpha.com/symbol/FOR' title='Forestar Group Inc.'>FOR</a>) for $17.75 per share in cash. The deal is expected to close in Q4, and D.R. Horton has cash and other immediately available capital on hand to close the $560M purchase.</li><li>Forestar will remain a publicly traded company, with former D.R. Horton CEO Donald Tomnitz to be executive chairman.</li><li>The deal is expected to be accretive to DHI's fiscal 2018 earnings.</li><li>Forestar's &nbsp;merger agreement with Starwood Capital Group has been terminated.</li><li>Forestar closed at $17.45 last night.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3275276-d-r-horton-lifts-bid-forestar-group\" target=\"_blank\">D.R. Horton lifts bid for Forestar Group</a> (June 23)</li></ul><div class=\"tiny-share-widget\" data-id=\"3276273\" data-linked=\"D.R. Horton inks merger deal with Forestar Group\" data-tweet=\"$DHI $DHI $FOR - D.R. Horton inks merger deal with Forestar Group https://seekingalpha.com/news/3276273-d-r-horton-inks-merger-deal-forestar-group?source=tweet\" data-url=\"https://seekingalpha.com/news/3276273-d-r-horton-inks-merger-deal-forestar-group\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:23 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276263\" data-ts=\"1498742532\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTI\" target=\"_blank\">PTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276263-proteostasis-therapeutics-reports-preliminary-data-from-phase-1-study-of-ptiminus-428-in-cf\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Proteostasis Therapeutics reports preliminary data from Phase 1 study of PTI-428 in CF patients; shares down 14% premarket on degree of lung function improvement</a></h4><ul><li>Proteostasis Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics'>PTI</a>) <a href=\"https://seekingalpha.com/pr/16875523-proteostasis-therapeutics-reports-preliminary-data-phase-1-study-ptiminus-428-patients-cystic\" target=\"_blank\">announces</a> preliminary data from the Multiple Ascending Dose cohort of its Phase 1 trial designed to evaluate the safety and pharmacokinetics of PTI-428 in cystic fibrosis &#40;CF&#41; subjects. PTI-428 is the Company&rsquo;s cystic fibrosis transmembrane conductance regulator &#40;CFTR&#41; amplifier.</li><li>The trial included 15 subjects in two patient populations, those who are taking Orkambi and those not taking CFTR modulator based therapies.</li>     <li>For the cohort with background Orkambi therapy, a total of ten patients with CF have been dosed to date. Primary endpoints of the study were safety, tolerability and pharmacokinetics &#40;PK&#41;. Patients were randomized to receive 100 mg PTI-428 or placebo for seven days in addition to their background Orkambi therapy.</li><li>Preliminary data confirmed the PTI-428 PK profile to be comparable to that achieved in healthy volunteers and showed a lack of impact on Orkambi exposure levels. The overall changes in lung function during the treatment period favored the test group but the changes compared to placebo were not statistically significant.</li>  <li>Further analysis of the study, including follow up on all patients enrolled in this cohort, is expected to be reported in July.</li>    <li>A separate study with a third patient population is initiating enrollment of CF patients who will receive PTI-428 or placebo in addition to Kalydeco as background therapy for 14 days. Proteostasis expects to announce preliminary results from this study in Q3.</li><li>Shares are down&nbsp;<font color='red'>14%</font>&nbsp;premarket on modest volume.</li>    </ul><div class=\"tiny-share-widget\" data-id=\"3276263\" data-linked=\"Proteostasis Therapeutics reports preliminary data from Phase 1 study of PTI-428 in CF patients; shares down 14% premarket on degree of lung function improvement\" data-tweet=\"$PTI - Proteostasis Therapeutics reports preliminary data from Phase 1 study of PTI-428 in CF patients; shares down 14% premarket on degree of lung function improvement https://seekingalpha.com/news/3276263-proteostasis-therapeutics-reports-preliminary-data-from-phase-1-study-of-ptiminus-428-in-cf?source=tweet\" data-url=\"https://seekingalpha.com/news/3276263-proteostasis-therapeutics-reports-preliminary-data-from-phase-1-study-of-ptiminus-428-in-cf\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276272\" data-ts=\"1498742398\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276272-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/INPX' title='Inpixon'>INPX</a> <font color='red'>-37%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16875628-inpixon-prices-6000-000-underwritten-public-offering\" target=\"_blank\">pricing</a> public offering.</li><li><a href='https://seekingalpha.com/symbol/FRED' title='Fred&#39;s, Inc.'>FRED</a>&nbsp;<font color='red'>-21%</font>&nbsp;on Walgreen Boots <a href=\"https://seekingalpha.com/pr/16875484-walgreens-boots-alliance-enters-agreement-rite-aid-buy-2186-rite-aid-stores-related-assets\" target=\"_blank\">terminating</a> agreement.</li><li><a href='https://seekingalpha.com/symbol/RAD' title='Rite Aid Corporation'>RAD</a>&nbsp;<font color='red'>-18%</font>&nbsp;on Walgreens <a href=\"https://seekingalpha.com/news/3276208-drugstore-shakeup-walgreens-rite-aid-strike-new-deal\" target=\"_blank\">replacing</a> store deal agreement.</li><li><a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a> <font color='red'>-13%</font>.</li><li><a href='https://seekingalpha.com/symbol/PIR' title='Pier 1 Imports Inc.'>PIR</a>&nbsp;<font color='red'>-13%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3276122-pier-1-imports-beats-0_01-misses-revenue\" target=\"_blank\">Q1 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/AVEO' title='AVEO Pharmaceuticals, Inc.'>AVEO</a> <font color='red'>-8%</font>.</li><li><a href='https://seekingalpha.com/symbol/AKBA' title='Akebia Therapeutics, Inc.'>AKBA</a>&nbsp;<font color='red'>-6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3276240-akebia-prices-stock-offering-14_50-shares-7-percent-premarket\" target=\"_blank\">pricing</a> public offering of 4M shares of common stock.</li><li><a href='https://seekingalpha.com/symbol/VHC' title='VirnetX Holding Corporation'>VHC</a> <font color='red'>-6%</font>.</li><li><a href='https://seekingalpha.com/symbol/DOC' title='Physicians Realty Trust'>DOC</a> <font color='red'>-6%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3276272\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$INPX $FRED $RAD - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3276272-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3276272-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276271\" data-ts=\"1498742309\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMNP\" target=\"_blank\">IMNP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276271-immune-pharma-almost-ceplene-deal-in-latin-america-shares-ahead-14-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Immune Pharma almost there with Ceplene deal in Latin America; shares ahead 14% premarket</a></h4><ul><li>Immune Pharmaceuticals (<a href='https://seekingalpha.com/symbol/IMNP' title='Immune Pharmaceuticals Inc.'>OTCQB:IMNP</a>) is up&nbsp;<font color='green'>14%</font>&nbsp; premarket on average volume in response to its <a href=\"https://seekingalpha.com/pr/16875735-immune-pharmaceuticals-oncology-subsidiary-cytovia-inc-provides-update-proposed-pint-pharma\" target=\"_blank\">announcement </a>that subsidiary Cytovia has reached substantial agreement with Pint Pharma S.A. on the material terms of a license and commercialization agreement for Ceplene in Latin America.</li><li>The deal will include a $4M investment in Cytovia by Pint.</li><li><strong>Update</strong>: On July 11, Cytovia <a href=\"https://seekingalpha.com/pr/16883740-cytovia-inc-immune-pharmaceuticals-oncology-subsidiary-enters-definitive-agreement-pint\" target=\"_blank\">announced </a>the signing of the agreement.</li></ul><div class=\"tiny-share-widget\" data-id=\"3276271\" data-linked=\"Immune Pharma almost there with Ceplene deal in Latin America; shares ahead 14% premarket\" data-tweet=\"$IMNP $IMNPQ - Immune Pharma almost there with Ceplene deal in Latin America; shares ahead 14% premarket https://seekingalpha.com/news/3276271-immune-pharma-almost-ceplene-deal-in-latin-america-shares-ahead-14-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3276271-immune-pharma-almost-ceplene-deal-in-latin-america-shares-ahead-14-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276270\" data-ts=\"1498742270\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276270-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/SPEX' title='Spherix Incorporated'>SPEX</a> <font color='green'>+66%</font>&nbsp;on being <a href=\"https://seekingalpha.com/news/3276253-spherix-bullish-hoth-eczema-drug-shares-50-percent-premarket\" target=\"_blank\">bullish</a> on Hoth eczema drug.</li>     <li><a href='https://seekingalpha.com/symbol/TROV' title='TrovaGene, Inc.'>TROV</a> <font color='green'>+15%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3276258-trovagene-18-percent-premarket-supply-deal-aml-candidate-pcmminus-075\" target=\"_blank\">supply</a> deal for AML candidate PCM-075.</li>     <li><a href='https://seekingalpha.com/symbol/IMNP' title='Immune Pharmaceuticals Inc.'>OTCQB:IMNP</a> <font color='green'>+13%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16875735-immune-pharmaceuticals-oncology-subsidiary-cytovia-inc-provides-update-proposed-pint-pharma\" target=\"_blank\">reaching</a> substantial agreement on the material terms of a licensing and commercialization agreement of Ceplene in&nbsp;Latin America&nbsp;with Pint Pharma S.A.</li>     <li><a href='https://seekingalpha.com/symbol/NXTD' title='NXT-ID Inc.'>NXTD</a> <font color='green'>+12%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16875117-nxt-id-subsidiary-fit-pay-power-payments-token\" target=\"_blank\">providing</a> payment capabilities for token.</li>     <li><a href='https://seekingalpha.com/symbol/GEMP' title='Gemphire Therapeutics'>GEMP</a> <font color='green'>+10%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3276125-gemphires-gemcabene-successful-mid-stage-hofh-study-shares-10-percent-hours\" target=\"_blank\">being</a> successful in mid-stage HoFH study.</li>     <li><a href='https://seekingalpha.com/symbol/STZ' title='Constellation Brands, Inc.'>STZ</a> <font color='green'>+9%</font>&nbsp;on Q1 <a href=\"https://seekingalpha.com/news/3276216-constellation-brands-beats-0_36-misses-revenue\" target=\"_blank\">earnings</a>.</li>     <li><a href='https://seekingalpha.com/symbol/CATB' title='Catabasis Pharmaceuticals'>CATB</a> <font color='green'>+6%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/WBA' title='Walgreens Boots Alliance, Inc.'>WBA</a> <font color='green'>+6%</font>&nbsp;on Q1 <a href=\"https://seekingalpha.com/news/3276202-walgreens-boots-beats-0_03-beats-revenue\" target=\"_blank\">earnings</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3276270\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$SPEX $TROV $IMNPQ - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3276270-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3276270-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276269\" data-ts=\"1498742087\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GRPN\" target=\"_blank\">GRPN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276269-grouponplus-2_9-b-riley-raises-to-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Groupon +2.9% as B. Riley raises to Buy</a></h4><ul>   <li>Groupon (NASDAQ:<a href='https://seekingalpha.com/symbol/GRPN' title='Groupon, Inc.'>GRPN</a>) is <font color='green'>up 2.9%</font> premarket alongside an upgrade to Buy at B. Riley, which points to upside from its international business.</li>    <li>Marketing spending should balance profitability and customer growth, according to analyst Sameet Sinha.</li>    <li>Sinha has boosted Groupon's price target to $5.50 from $4.20, implying 60% upside.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3276269\" data-linked=\"Groupon +2.9% as B. Riley raises to Buy\" data-tweet=\"$GRPN - Groupon +2.9% as B. Riley raises to Buy https://seekingalpha.com/news/3276269-grouponplus-2_9-b-riley-raises-to-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3276269-grouponplus-2_9-b-riley-raises-to-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276258\" data-ts=\"1498740914\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TROV\" target=\"_blank\">TROV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276258-trovagene-up-18-premarket-on-supply-deal-for-aml-candidate-pcmminus-075\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trovagene up 18% premarket on supply deal for AML candidate PCM-075</a></h4><ul><li>Nano cap Trovagene (NASDAQ:<a href='https://seekingalpha.com/symbol/TROV' title='TrovaGene, Inc.'>TROV</a>) is poised to add its recent up move. Shares have almost doubled this month in response to several deals related to its ctDNA tests and the advancement of AML candidate PCM-075.</li><li>Shares are up&nbsp;<font color='green'>18%</font>&nbsp;premarket this morning on the heels of its announcement of a <a href=\"https://seekingalpha.com/pr/16875648-trovagene-announces-manufacturing-agreement-nerpharma-supply-pcmminus-075-aml-trial\" target=\"_blank\">supplier agreement</a> with Milan, Italy-based Nerviano Medical Sciences S.r.L. subsidiary NerPharMa, S.r.l. to supply PCM-075 for clinical trials and commercial demand, if approved.</li></ul><div class=\"tiny-share-widget\" data-id=\"3276258\" data-linked=\"Trovagene up 18% premarket on supply deal for AML candidate PCM-075\" data-tweet=\"$TROV - Trovagene up 18% premarket on supply deal for AML candidate PCM-075 https://seekingalpha.com/news/3276258-trovagene-up-18-premarket-on-supply-deal-for-aml-candidate-pcmminus-075?source=tweet\" data-url=\"https://seekingalpha.com/news/3276258-trovagene-up-18-premarket-on-supply-deal-for-aml-candidate-pcmminus-075\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276253\" data-ts=\"1498740227\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPEX\" target=\"_blank\">SPEX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276253-spherix-bullish-on-hoth-eczema-drug-shares-up-50-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Spherix bullish on Hoth eczema drug; shares up 50% premarket</a></h4><ul><li>Thinly traded nano cap Spherix (NASDAQ:<a href='https://seekingalpha.com/symbol/SPEX' title='Spherix Incorporated'>SPEX</a>) jumps&nbsp;<font color='green'>50%</font>&nbsp;premarket on robust volume on the heels of the release of a <a href=\"https://seekingalpha.com/pr/16872621-spherix-issues-letter-shareholders\" target=\"_blank\">shareholder letter </a>from CEO Anthony Hayes.</li><li>He says the company does not anticipate having to invest any more money in Hoth Therapeutics to support the development of its eczema candidate. He adds that Hoth should be able to pursue the abbreviated regulatory pathway 505(b)(2) in the U.S.</li><li>He predicts a winner, citing relatively recent M&amp;A deals in topical dermatology space as evidence of the market opportunity.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3274549-spherix-takes-controlling-interest-hoth-therapeutics-shares-ahead-6-percent\" target=\"_blank\">Spherix takes controlling interest in Hoth Therapeutics; shares ahead 6%</a> (June 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3276253\" data-linked=\"Spherix bullish on Hoth eczema drug; shares up 50% premarket\" data-tweet=\"$SPEX - Spherix bullish on Hoth eczema drug; shares up 50% premarket https://seekingalpha.com/news/3276253-spherix-bullish-on-hoth-eczema-drug-shares-up-50-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3276253-spherix-bullish-on-hoth-eczema-drug-shares-up-50-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:43 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276254\" data-ts=\"1498739778\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AYI\" target=\"_blank\">AYI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276254-acuity-brands-beats-0_12-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Acuity Brands beats by $0.12, beats on revenue</a></h4><ul><li>Acuity Brands (NYSE:<a href='https://seekingalpha.com/symbol/AYI' title='Acuity Brands, Inc. &#40;Holding Company&#41;'>AYI</a>): Q3 EPS of $2.15 <font color='green'>beats by $0.12</font>.</li><li>Revenue of $891.6M (+4.7% Y/Y) <font color='green'>beats by $12.41M</font>.</li><li>Shares <font color='green'>+5.66%</font> PM.</li><li><a href='https://seekingalpha.com/pr/16875762-acuity-brands-reports-fiscal-2017-third-quarter-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3276254\" data-linked=\"Acuity Brands beats by $0.12, beats on revenue\" data-tweet=\"$AYI - Acuity Brands beats by $0.12, beats on revenue https://seekingalpha.com/news/3276254-acuity-brands-beats-0_12-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3276254-acuity-brands-beats-0_12-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:36 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276240\" data-ts=\"1498738829\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKBA\" target=\"_blank\">AKBA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276240-akebia-prices-stock-offering-14_50-shares-down-7-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Akebia prices stock offering at $14.50; shares down 7% premarket</a></h4><ul><li>Akebia Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AKBA' title='Akebia Therapeutics, Inc.'>AKBA</a>) eases&nbsp;<font color='red'>7%</font>&nbsp;premarket on light volume in response to the <a href=\"https://seekingalpha.com/pr/16875353-akebia-announces-pricing-public-offering-common-stock\" target=\"_blank\">pricing </a>of its public offering of 4M shares of common stock at $14.50 per share. Underwriters over-allotment is an additional 600K shares. Closing date is July 5.</li><li>Net proceeds will fund the continued clinical development of vadadustat, build-out of manufacturing, clinical development of AKB-5169, the development of other pipeline candidates, working capital and general corporate purposes.</li><li>Yesterday's close was $15.50.</li></ul><div class=\"tiny-share-widget\" data-id=\"3276240\" data-linked=\"Akebia prices stock offering at $14.50; shares down 7% premarket\" data-tweet=\"$AKBA - Akebia prices stock offering at $14.50; shares down 7% premarket https://seekingalpha.com/news/3276240-akebia-prices-stock-offering-14_50-shares-down-7-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3276240-akebia-prices-stock-offering-14_50-shares-down-7-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:20 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276234\" data-ts=\"1498737982\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAG\" target=\"_blank\">CAG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276234-on-conagra-foods-q4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on ConAgra Foods&#39; Q4</a></h4><ul>     <li>ConAgra Foods (NYSE:<a href='https://seekingalpha.com/symbol/CAG' title='ConAgra Brands, Inc.'>CAG</a>) reports net sales fell 9.3% in <a href=\"https://seekingalpha.com/pr/16875543-conagra-brands-transformation-continues-solid-end-strong-fiscal-2017\" target=\"_blank\">Q4</a>&nbsp;primarily as a result of volume declines associated with the Company's actions to build a higher quality revenue base.</li>     <li>Segment net sales:&nbsp;Grocery &amp; Snacks: $749.4M (-3%);&nbsp;Refrigerated &amp; Frozen: $640.2M (-5.1%);&nbsp;International: $204.7M (-1.3%);&nbsp;Foodservice: $267.4M (-5.3%).</li>     <li>Adjusted gross margin rate improved 130 bps to 29%.</li>     <li>The Company expects to repurchase approximately $1.1B of shares of its common stock in FY2018.</li>     <li><b>FY2018 Guidance</b>: Net sales: -2% to flat; Adjusted operating margin rate: 15.9% to 16.3%; Tax rate: 32.5% to 33.5%; Adjusted EPS: $1.84 to $1.89.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3276234\" data-linked=\"More on ConAgra Foods&#39; Q4\" data-tweet=\"$CAG - More on ConAgra Foods&#39; Q4 https://seekingalpha.com/news/3276234-on-conagra-foods-q4?source=tweet\" data-url=\"https://seekingalpha.com/news/3276234-on-conagra-foods-q4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276233\" data-ts=\"1498737877\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FRED\" target=\"_blank\">FRED</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276233-next-for-freds\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">What&#39;s next for Fred&#39;s?</a></h4><ul> <li>Shares of Fred's (NASDAQ:<a href='https://seekingalpha.com/symbol/FRED' title='Fred&#39;s, Inc.'>FRED</a>) are <font color='red'>down 19.64%</font> in premarket action after the rug was pulled out from the company's plan to add Rite Aid stores.</li><li>Investors will now assess what's next for Fred's as the landscape in the sector abruptly shifted with today's development.</li> <li>The drug store operator fired off a poison pill yesterday, an action that indicates that it's not looking for a buyout.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3276233\" data-linked=\"What&#39;s next for Fred&#39;s?\" data-tweet=\"$FRED - What&#39;s next for Fred&#39;s? https://seekingalpha.com/news/3276233-next-for-freds?source=tweet\" data-url=\"https://seekingalpha.com/news/3276233-next-for-freds\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276231\" data-ts=\"1498737696\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COF\" target=\"_blank\">COF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276231-financial-sector-set-for-another-big-day-after-ccar\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financial sector set for another big day after CCAR</a></h4><ul><li>Perhaps the good news wasn't yet priced in. The <a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a> is&nbsp;<font color='green'>higher by 2.1%</font>&nbsp;and the <a href='https://seekingalpha.com/symbol/KRE' title='SPDR S&P Regional Banking ETF'>KRE</a> by&nbsp;<font color='green'>2%</font>&nbsp;as all 34 lenders subject to the CCAR had their capital return plans <a href=\"https://seekingalpha.com/news/3276130-banks-see-capital-return-plans-cleared\" target=\"_blank\">approved by the Fed</a> last night.</li><li>Capital One (NYSE:<a href='https://seekingalpha.com/symbol/COF' title='Capital One Financial Corporation'>COF</a>) is an outlier,&nbsp;<font color='red'>down 0.7%</font>&nbsp;premarket after winning only conditional approval.</li><li>\"The highly <a href=\"https://www.bloomberg.com/news/articles/2017-06-28/capital-one-must-resubmit-plan-as-33-banks-ace-fed-stress-tests\" target=\"_blank\">positive report card puts</a> more wind at the backs of the Trump administration and others who want to soften Dodd-Frank-era regulations,\" says Ian Katz of Capital Alpha Partners.</li><li>Citigroup (NYSE:<a href='https://seekingalpha.com/symbol/C' title='Citigroup Inc.'>C</a>) is&nbsp;<font color='green'>ahead 3.2%</font>&nbsp;after doubling its quarterly payout to $0.32 per share. Bank of America (NYSE:<a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a>)&nbsp;<font color='green'>up 3%</font>&nbsp;after lifting its dividend 60% to $0.12. Morgan Stanley (NYSE:<a href='https://seekingalpha.com/symbol/MS' title='Morgan Stanley'>MS</a>)&nbsp;<font color='green'>up 2.4%</font>&nbsp;after raising its dividend 25% to $0.25.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a>, <a href='https://seekingalpha.com/symbol/FAS' title='Direxion Daily Financial Bull 3x Shares ETF'>FAS</a>, <a href='https://seekingalpha.com/symbol/FAZ' title='Direxion Daily Financial Bear 3x Shares ETF'>FAZ</a>, <a href='https://seekingalpha.com/symbol/VFH' title='Vanguard Financials ETF'>VFH</a>, <a href='https://seekingalpha.com/symbol/UYG' title='ProShares Ultra Financials ETF'>UYG</a>, <a href='https://seekingalpha.com/symbol/IYF' title='iShares U.S. Financials ETF'>IYF</a>, <a href='https://seekingalpha.com/symbol/FNCL' title='Fidelity MSCI Financials Index ETF'>FNCL</a>, <a href='https://seekingalpha.com/symbol/BTO' title='John Hancock Financial Opportunity Fund'>BTO</a>, <a href='https://seekingalpha.com/symbol/IYG' title='iShares U.S. Financial Services ETF'>IYG</a>, <a href='https://seekingalpha.com/symbol/FXO' title='First Trust Financials AlphaDEX ETF'>FXO</a>, <a href='https://seekingalpha.com/symbol/SEF' title='ProShares Short Financials ETF'>SEF</a>, <a href='https://seekingalpha.com/symbol/RYF' title='Invesco S&P Equal Weight Financial ETF'>RYF</a>, <a href='https://seekingalpha.com/symbol/FINU' title='ProShares UltraPro Financials ETF'>FINU</a>, <a href='https://seekingalpha.com/symbol/XLFS' title='Financial Services Select Sector SPDR ETF'>XLFS</a>, <a href='https://seekingalpha.com/symbol/FINZ' title='ProShares UltraPro Short Financials ETF'>FINZ</a>, <a href='https://seekingalpha.com/symbol/RWW' title='Oppenheimer Financials Sector Revenue ETF'>RWW</a>, <a href='https://seekingalpha.com/symbol/FAZZ' title='Direxion Daily Financial Bear 1x Shares ETF'>FAZZ</a>, <a href='https://seekingalpha.com/symbol/JHMF' title='John Hancock Multifactor Financials ETF'>JHMF</a>, <a href='https://seekingalpha.com/symbol/FNCF' title='iShares Edge MSCI Multifactor Financials ETF'>FNCF</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3276231\" data-linked=\"Financial sector set for another big day after CCAR\" data-tweet=\"$COF $XLF $KRE - Financial sector set for another big day after CCAR https://seekingalpha.com/news/3276231-financial-sector-set-for-another-big-day-after-ccar?source=tweet\" data-url=\"https://seekingalpha.com/news/3276231-financial-sector-set-for-another-big-day-after-ccar\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276227\" data-ts=\"1498737417\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STZ\" target=\"_blank\">STZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276227-strong-u-s-beer-results-lift-constellation-brands\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Strong U.S. beer results lift Constellation Brands</a></h4><ul> <li>Constellations Brands (NYSE:<a href='https://seekingalpha.com/symbol/STZ' title='Constellation Brands, Inc.'>STZ</a>) races higher after cruising past profit estimates with its <a href=\"http://www.cbrands.com/news-media/constellation-brands-reports-first-quarter-fiscal-2018-results\" target=\"_blank\">FQ1 report</a>.</li> <li>Beer sales were up 8% while sales of wines and spirits fell 4%. Operating margin popped 530 bps to 34.6% of sales. \"Excellent execution\" in the U.S. during the Cinco de Mayo and Memorial Day holidays was cited by Constellation management.</li> <li>Looking ahead, Constellation sees FY18 adjusted EPS of $7.90 to $8.10.</li> <li>STZ <font color='green'>+4.56%</font> premarket to $192.05.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3276227\" data-linked=\"Strong U.S. beer results lift Constellation Brands\" data-tweet=\"$STZ - Strong U.S. beer results lift Constellation Brands https://seekingalpha.com/news/3276227-strong-u-s-beer-results-lift-constellation-brands?source=tweet\" data-url=\"https://seekingalpha.com/news/3276227-strong-u-s-beer-results-lift-constellation-brands\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276224\" data-ts=\"1498737230\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HSBC\" target=\"_blank\">HSBC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276224-hsbc-up-5-after-ccar\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">HSBC up more than 5% after CCAR</a></h4><ul><li>Investors are prepping<a href=\"https://www.bloomberg.com/news/articles/2017-06-29/hsbc-surges-after-u-s-stress-test-pass-boosts-payout-prospects?cmpid=socialflow-twitter-business&amp;utm_content=business&amp;utm_campaign=socialflow-organic&amp;utm_source=twitter&amp;utm_medium=social\" target=\"_blank\"> for maybe more than</a> $3B in capital returns from HSBC (NYSE:<a href='https://seekingalpha.com/symbol/HSBC' title='HSBC Holdings PLC'>HSBC</a>) after the lender passed the Fed's CCAR.</li><li>KBW's Richard Smith estimates a full $7B of excess capital \"trapped\" in the U.S., but says it will take some time to repatriate all of that. And don't forget the dividend yield of nearly 6%.</li><li>Shares are&nbsp;<font color='green'>higher by 5.5%&nbsp;</font>in London action to a four-year high. The ADRs are&nbsp;<font color='green'>up 5.25%</font>&nbsp;premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3276224\" data-linked=\"HSBC up more than 5% after CCAR\" data-tweet=\"$HSBC - HSBC up more than 5% after CCAR https://seekingalpha.com/news/3276224-hsbc-up-5-after-ccar?source=tweet\" data-url=\"https://seekingalpha.com/news/3276224-hsbc-up-5-after-ccar\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276220\" data-ts=\"1498736582\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RIO\" target=\"_blank\">RIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276220-rio-tinto-shareholders-ok-sale-of-australian-thermal-coal-assets-to-yancoal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rio Tinto shareholders OK sale of Australian thermal coal assets to Yancoal</a></h4><ul>     <li>Rio Tinto (NYSE:<a href='https://seekingalpha.com/symbol/RIO' title='Rio Tinto plc'>RIO</a>)&nbsp;<font color='green'>+2%</font> premarket after shareholders <a href=\"http://www.reuters.com/article/us-rio-tinto-divestiture-yancoal-idUSKBN19K0E7\" target=\"_blank\">approve the sale of Australian coal assets</a> to China-backed Yancoal Australia (<a href='https://seekingalpha.com/symbol/YACAF' title='Yancoal Australia Ltd'>OTC:YACAF</a>, <a href='https://seekingalpha.com/symbol/YZC' title='Yanzhou Coal Mining Co. Ltd.'>YZC</a>) for $2.69B, ending the bidding war with Glencore (<a href='https://seekingalpha.com/symbol/GLCNF' title='Glencore Plc'>OTCPK:GLCNF</a>, <a href='https://seekingalpha.com/symbol/GLNCY' title='Glencore Plc ADR'>OTCPK:GLNCY</a>).</li>     <li>Rio had highlighted a range of advantages in Yancoal's <a href=\"https://seekingalpha.com/news/3275431-rio-maintains-support-yancoal-glencore-coal-sale\" target=\"_blank\">recently improved offer</a>, which it said included a better chance of completion, a $225M breakup fee and a faster and more certain timetable that closes the transaction in Q3.</li>     <li>Rio Chairman Jan du Plessis says funds from the sale have yet to be allocated within the company, as some shareholders want to use the money to boost dividends or buy back shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3276220\" data-linked=\"Rio Tinto shareholders OK sale of Australian thermal coal assets to Yancoal\" data-tweet=\"$RIO $RIO $YACAF - Rio Tinto shareholders OK sale of Australian thermal coal assets to Yancoal https://seekingalpha.com/news/3276220-rio-tinto-shareholders-ok-sale-of-australian-thermal-coal-assets-to-yancoal?source=tweet\" data-url=\"https://seekingalpha.com/news/3276220-rio-tinto-shareholders-ok-sale-of-australian-thermal-coal-assets-to-yancoal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:43 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276218\" data-ts=\"1498736509\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276218-oppenheimer-sees-42-amzn-offer-for-whole-foods-market-holding-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oppenheimer sees $42 AMZN offer for Whole Foods Market holding up</a></h4><ul> <li>Oppenheimer downgrades Whole Foods Market (WFM) to Perform from Outperform as it lowers the odds of a new buyer coming in with an offer to top Amazon.</li> <li>Source: Bloomberg</li> <li>Shares of Whole Foods Market are <font color='red'>down 0.36%</font> premarket to $42.10 as the M&amp;A premium over Amazon's $42 bid tightens again.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3276218\" data-linked=\"Oppenheimer sees $42 AMZN offer for Whole Foods Market holding up\" data-tweet=\"$AMZN - Oppenheimer sees $42 AMZN offer for Whole Foods Market holding up https://seekingalpha.com/news/3276218-oppenheimer-sees-42-amzn-offer-for-whole-foods-market-holding-up?source=tweet\" data-url=\"https://seekingalpha.com/news/3276218-oppenheimer-sees-42-amzn-offer-for-whole-foods-market-holding-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276217\" data-ts=\"1498736361\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHC\" target=\"_blank\">BHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276217-valeant-completes-dendreon-sale-to-sanpower-for-820m-cantor-bullish-boosts-price-target-to-23\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Valeant completes Dendreon sale to Sanpower for ~$820M; Cantor bullish, boosts price target to $23; shares ahead 4% premarket</a></h4><ul><li>Valeant Pharmaceuticals (VRX) is up&nbsp;<font color='green'>4%&nbsp;</font>premarket on average volume. The company announced that it has <a href=\"https://seekingalpha.com/pr/16875506-valeant-pharmaceuticals-completes-sale-dendreon-sanpower-group\" target=\"_blank\">completed the sale</a> of Dendreon to Sanpower Group for $819.9M.</li><li>After the close yesterday, Cantor Fitzgerald <a href=\"https://www.streetinsider.com/Analyst+Comments/Valeant+Pharmaceuticals+%28VRX%29+PT+Raised+to+%2423+at+Cantor+Fitzgerald/13055411.html\" target=\"_blank\">raised its price target </a>to $23 (34% upside) from $18 while maintaining its Overweight rating saying the company's \"execution has continued to meet/exceed our expectations.\" Analyst Louis Chen cites positive script trends for Salix, progress on debt refinancing, shareholder support on executive compensation, the addition of John Paulson to the board &nbsp;and a promising pipeline as reasons to be bullish.</li></ul><div class=\"tiny-share-widget\" data-id=\"3276217\" data-linked=\"Valeant completes Dendreon sale to Sanpower for ~$820M; Cantor bullish, boosts price target to $23; shares ahead 4% premarket\" data-tweet=\"$BHC - Valeant completes Dendreon sale to Sanpower for ~$820M; Cantor bullish, boosts price target to $23; shares ahead 4% premarket https://seekingalpha.com/news/3276217-valeant-completes-dendreon-sale-to-sanpower-for-820m-cantor-bullish-boosts-price-target-to-23?source=tweet\" data-url=\"https://seekingalpha.com/news/3276217-valeant-completes-dendreon-sale-to-sanpower-for-820m-cantor-bullish-boosts-price-target-to-23\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>194&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276215\" data-ts=\"1498736227\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PFODF\" target=\"_blank\">PFODF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276215-premier-foods-rallies-after-report-of-strategic-review\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premier Foods rallies after report of strategic review</a></h4><ul> <li>Premier Foods (<a href='https://seekingalpha.com/symbol/PFODF' title='Premier Foods Plc.'>OTCPK:PFODF</a>, <a href='https://seekingalpha.com/symbol/PRRFY' title='Premier Foods Plc. ADR'>OTCPK:PRRFY</a>) is carrying out a <a href=\"https://www.wsj.com/articles/premier-foods-review-puts-options-on-the-table-1498734953\" target=\"_blank\">strategic review</a>, including considering a sale of some of its brands, according to The Wall Street Journal.</li> <li>Sources indicate that Credit Suisse was hired by Premier Foods to assist it in the process.</li><li>Shares of Premier Foods are&nbsp;<font color='green'>up 5.62%</font>&nbsp;in London trading.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3276215\" data-linked=\"Premier Foods rallies after report of strategic review\" data-tweet=\"$PFODF $PFODF $PRRFY - Premier Foods rallies after report of strategic review https://seekingalpha.com/news/3276215-premier-foods-rallies-after-report-of-strategic-review?source=tweet\" data-url=\"https://seekingalpha.com/news/3276215-premier-foods-rallies-after-report-of-strategic-review\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:37 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276208\" data-ts=\"1498735303\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WBA\" target=\"_blank\">WBA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276208-drugstore-shakeup-walgreens-and-rite-aid-strike-new-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Drugstore shakeup: Walgreens and Rite Aid strike new deal</a></h4><ul>     <li>Walgreen Boots Alliance (NASDAQ:<a href='https://seekingalpha.com/symbol/WBA' title='Walgreens Boots Alliance, Inc.'>WBA</a>) and Rite Aid (NYSE:<a href='https://seekingalpha.com/symbol/RAD' title='Rite Aid Corporation'>RAD</a>) work out a store deal to replace the merger agreement between the two companies.</li>     <li>Under the terms of the deal, Walgreen will acquire 2,186 Rite Aid stores and related assets for $5.175B.</li>     <li>Walgreen expects synergies of +$400M from the acquired store strategy.</li>     <li>\"This new transaction extends our growth strategy and offers additional operational and financial benefits,&rdquo; says Walgreens CEO Stefano Pessina.</li>     <li>Rite Aid earns a $325M termination fee from the cancellation of the old deal.</li><li>Fred's is left out in the cold.</li>     <li>Source: <a href=\"https://seekingalpha.com/pr/16875484-walgreens-boots-alliance-enters-agreement-rite-aid-buy-2186-rite-aid-stores-related-assets\" target=\"_blank\">Press Release</a></li>     <li>Premarket action: RAD&nbsp;<font color='red'>-4.07%</font>&nbsp;to $3.77, WBA&nbsp;<font color='green'>+3.72%</font>&nbsp;to $79.96, Fred's (NASDAQ:<a href='https://seekingalpha.com/symbol/FRED' title='Fred&#39;s, Inc.'>FRED</a>)&nbsp;<font color='red'>-24.76%</font>&nbsp;to $9.27.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3276208\" data-linked=\"Drugstore shakeup: Walgreens and Rite Aid strike new deal\" data-tweet=\"$WBA $WBA $RAD - Drugstore shakeup: Walgreens and Rite Aid strike new deal https://seekingalpha.com/news/3276208-drugstore-shakeup-walgreens-and-rite-aid-strike-new-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3276208-drugstore-shakeup-walgreens-and-rite-aid-strike-new-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>233&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276197\" data-ts=\"1498733258\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MKC\" target=\"_blank\">MKC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276197-on-mccormicks-q2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on McCormick&#39;s Q2</a></h4><ul>     <li>McCormick (NYSE:<a href='https://seekingalpha.com/symbol/MKC' title='McCormick & Company, Inc.'>MKC</a>)&nbsp;reports sales rose 7% on a constant currency basis in <a href=\"https://seekingalpha.com/pr/16875468-mccormick-reports-strong-sales-profit-growth-second-quarter\" target=\"_blank\">Q2</a>.</li>     <li>Acquisition contributed 3 percentage point of growth in the quarter.</li>     <li>Segment revenue: Consumer: $656.4M (+2%, +4% on a constant currency basis); Industrial: $457.9M (+9%, +12% on a&nbsp;constant currency basis).</li>     <li>Gross margin rate fell 80 bps to 39.9%.</li>     <li>Segment operating income: Consumer: $91.3M (+6%); Industrial: $46M (+8%).</li>     <li>Adjusted operating margin rate improved 20 bps to 12.3%.</li>     <li>Income from unconsolidated operations increased 9.1% to $8.4M.</li>     <li><b>FY2017 Guidance</b>:&nbsp;Sales: &nbsp;+4% to +6% (+5% to +7% in constant currency); Operating income: +8% to +10%; Adjusted operating income: +8% to +10%; Diluted EPS: $3.94 to $4.02; Adjusted diluted EPS: $4.05 to $4.13.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3276197\" data-linked=\"More on McCormick&#39;s Q2\" data-tweet=\"$MKC - More on McCormick&#39;s Q2 https://seekingalpha.com/news/3276197-on-mccormicks-q2?source=tweet\" data-url=\"https://seekingalpha.com/news/3276197-on-mccormicks-q2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3276190\" data-ts=\"1498731768\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GBX\" target=\"_blank\">GBX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3276190-on-greenbriers-q3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Greenbrier&#39;s Q3</a></h4><ul>     <li>Greenbrier (NYSE:<a href='https://seekingalpha.com/symbol/GBX' title='The Greenbrier Companies, Inc.'>GBX</a>) reports Manufacturing revenue squeezed 30.8% to $317.1M in <a href=\"https://seekingalpha.com/pr/16875443-greenbrier-reports-third-quarter-results\" target=\"_blank\">Q3</a>.</li>     <li>Wheels &amp; Parts revenue rose 8.7% to $85.23M.</li>     <li>Leasing &amp; Services revenue declined 51.5% to $36.83M.</li>     <li>Gross margin rate slipped 30 bps to 20.4%.</li>     <li>SG&amp;A expense rate grew 260 bps to 9.7%.</li>     <li>Operating margin rate down 270 bps to 11%.</li>     <li>New rail car deliveries -33.3% Q/Q to 2,600 units.</li>     <li>New railcar manufacturing backlog was 31K units valued at $3.1B at quarter's end, vs. 22.6K units valued at $2.44B as of Feb. 28.</li>     <li><b>FY2017 Guidance</b>: Deliveries: ~15,000 to 16,000 units; Revenues: $2.1B to $2.3B; Diluted EPS: $3.45 to $3.65.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3276190\" data-linked=\"More on Greenbrier&#39;s Q3\" data-tweet=\"$GBX - More on Greenbrier&#39;s Q3 https://seekingalpha.com/news/3276190-on-greenbriers-q3?source=tweet\" data-url=\"https://seekingalpha.com/news/3276190-on-greenbriers-q3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:22 AM </div></div></li>","count":65,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}